Therapeutic use of mitochondria and combined mitochondrial agents
Pharmaceutical compositions using isolated mitochondria or combined agents address the lack of treatments for mitochondrial damage by enabling targeted delivery and therapeutic applications, enhancing diagnostic imaging and drug delivery through vascular integration.
Patent Information
- Application Number
- JP2024139388
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-11-10
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-19
AI Technical Summary
Current treatments for mitochondrial damage and dysfunction are lacking, and there is a need for therapeutic, diagnostic, and drug delivery methods utilizing mitochondria.
Pharmaceutical compositions comprising isolated mitochondria or combined mitochondrial agents, which can be administered via injection or infusion into a patient's blood vessels, allowing for targeted delivery and distribution within tissues for therapeutic, diagnostic, or imaging purposes.
The methods enable effective treatment of various disorders, including ischemia-related diseases, cardiotoxicity, and mitochondrial defects, as well as diagnostic imaging and drug delivery, by utilizing mitochondria's ability to cross the vascular endothelium and integrate into cells.
Smart Images

Figure 2024161552000001_ABST
Abstract
Description
[Technical Field]
[0001] Priority claims This application claims the benefit of U.S. Provisional Application No. 62 / 279,442, filed January 15, 2016, U.S. Provisional Application No. 62 / 279,489, filed January 15, 2016, and U.S. Provisional Application No. 62 / 420,381, filed November 10, 2016, the entire contents of which are incorporated herein by reference.
[0002] Statement Regarding Federally Sponsored Research This disclosure was made with government support from the National Institutes of Health, National Heart, Lung and Blood Institute, U.S. Public Health Service under Grant No. HL103642, and from the National Heart, Lung and Blood Institute under Grant Nos. HL29077 and HL068915. The U.S. government may have certain rights in this invention.
[0003] Field The present disclosure relates to the therapeutic use of mitochondria and combined mitochondrial agents. [Background technology]
[0004] background Mitochondria are double-membrane-bound organelles found in the cytoplasm of nucleated eukaryotic cells. They are found in nearly all cells in the human body except red blood cells. They are the primary site of cellular energy metabolism and generate adenosine triphosphate (ATP) for various cellular functions. Typically, more than 90% of a cell's ATP needs are supplied by the cell's own mitochondria.
[0005] Mitochondria consist of two concentric membranes with specialized functions: the inner mitochondrial membrane contains the proteins for ATP synthase, and the outer mitochondrial membrane, which contains numerous integral membrane proteins, encases the entire organelle.
[0006] The structure of mitochondria bears striking similarities to some modern prokaryotes. In fact, mitochondria are thought to have arisen from an ancient symbiosis in which a nucleated cell engulfed an aerobic prokaryote. In this symbiotic relationship, the host cell became dependent on the engulfed prokaryote for energy production, and the prokaryote began to rely on the protective environment provided by the host cell.
[0007] Due to the key function of mitochondria in cellular metabolism, mitochondrial damage and dysfunction can lead to a variety of human diseases. Diseases caused by mutations in mitochondrial DNA (mtDNA) include Kearns-Sayre syndrome, MELAS syndrome, and Leber's hereditary optic neuropathy. These diseases are often transmitted from mother to child. Furthermore, diseases such as Kearns-Sayre syndrome, Pearson syndrome, and progressive external ophthalmoplegia are thought to result from large-scale mtDNA rearrangements.
[0008] Furthermore, mitochondrial damage and dysfunction can also be caused by acquired mitochondrial diseases. These acquired mitochondrial diseases can be caused by injury, toxicity, chemotherapy, and age-related changes. In particular, ischemia / reperfusion injury can cause mitochondrial damage, which will have a negative impact on oxygen consumption and energy synthesis.
[0009] Currently, there are no known and approved treatments that utilize mitochondria. There is a need for such treatments. There is also a need to utilize mitochondria for drug delivery and several other therapeutic and diagnostic purposes. Summary of the Invention
[0010] overview The present disclosure provides pharmaceutical compositions containing mitochondria and methods for treating disorders using such pharmaceutical compositions. The present disclosure further provides diagnostic and imaging methods using such pharmaceutical compositions. The described methods are based, at least in part, on the discovery that isolated mitochondria, as well as isolated mitochondria linked to therapeutic, diagnostic, and / or imaging agents, can be delivered to a patient's tissues by injecting them into the patient's blood vessels. That is, while contemplated by certain methods described herein, direct injection or application of mitochondria to target tissues is not always necessary. Rather, in some cases, the methods described herein take advantage of the discovery that after mitochondria are injected or infused, for example, into an artery, they can cross the arterial wall and be taken up by cells in the patient's tissues. The methods described herein can provide local and global distribution of mitochondria, or mitochondria linked to therapeutic, diagnostic, and / or imaging agents, to tissues or cells for various treatment, diagnosis, and / or imaging purposes using relatively simple medical procedures.
[0011] In one aspect, the present disclosure relates to a method for treating a subject with ischemia-related disease.The method comprises administering to the subject a therapeutically effective amount of a composition comprising isolated mitochondria or a combination of mitochondrial agents, for example, by direct injection, by vascular infusion, and / or by injecting the composition into the blood vessel of the subject.The ischemia-related disease can be any disease that involves ischemia, for example, acute coronary syndrome, myocardial infarction, hepatic ischemia-reperfusion injury, or ischemic injury-compartment syndrome.
[0012] The combined mitochondrial agent can include a pharmaceutical, diagnostic, imaging, or therapeutic agent, or any other agent. An imaging agent can be a radioactive, fluorescent, or any agent that is detectable by magnetic resonance imaging (MRI), such as 18 F-rhodamine 6G or iron oxide nanoparticles.
[0013] In certain embodiments, the blood vessel is a blood vessel or part of the vascular system that carries blood to a target site, organ, or region, e.g., a coronary artery of a subject, a hepatic portal vein of a subject, a great pancreatic artery of a subject, or a prostatic artery of a subject.
[0014] In certain embodiments, the mitochondria can have different sources, for example, the mitochondria can be autogeneic, allogeneic, or xenogeneic. In certain embodiments, the autogeneic mitochondria can have exogenous mtDNA. In some embodiments, the mitochondria are derived from a first-degree relative of the subject.
[0015] In some embodiments, the described methods include collecting the isolated mitochondria from the cells prior to administration. The isolated mitochondria or combined mitochondrial agents can be administered to the subject immediately after the isolated mitochondria are collected from the cells.
[0016] In another aspect, the present disclosure relates to a method for minimizing cardiac toxicity from chemotherapy.The method comprises administering to a subject a therapeutically effective amount of pharmaceutical composition comprising isolated mitochondria or a combined mitochondrial agent before (for example, immediately before), during, or after the subject's chemotherapy treatment.The composition can be administered to a subject by various routes, for example, by direct injection, by intravascular injection, or by injecting the composition into the subject's blood vessel.The combined mitochondrial agent can further comprise a pharmaceutical substance.In certain embodiments, the blood vessel is the subject's coronary artery.
[0017] In yet another aspect, the present disclosure relates to a method for delivering an active substance to a target site in a subject. The method includes administering a therapeutically effective amount of a combined mitochondrial agent to a blood vessel of the subject. The target site can be any part of the subject, such as the heart, kidney, pancreas, lung, optic nerve, brain, or skeletal muscle. In these methods, the blood vessel is a part of the subject's vascular system that carries blood to the target site. The delivered active substance can be a pharmaceutical substance, a diagnostic substance, an imaging substance, or a therapeutic substance, an antibody or antigen-binding fragment, or any other active substance. The active substance and the mitochondria are in physical contact with each other; for example, the active substance can be linked to the mitochondria (e.g., by a covalent bond), embedded in the mitochondria, attached to the mitochondria, embedded in the mitochondrial membrane, substantially encapsulated within the mitochondria, or completely enclosed by the mitochondria.
[0018] In yet another aspect, the present disclosure relates to a method for imaging a tissue of a subject, the method comprising administering to the subject an effective amount of a combined mitochondrial agent comprising an imaging agent; and imaging the tissue of the subject by an imaging technique. The imaging agent may be a radioactive substance, a fluorescent substance, or any agent detectable by MRI, such as 18F-rhodamine 6G or iron oxide nanoparticles. The imaging technique can be, for example, positron emission tomography (PET), computed tomography (CT), micro-computed tomography (μCT), PET / CT, PET / MRI, fluorescence molecular tomography (FMT), or FMT / CT.
[0019] In one aspect, the present disclosure relates to a method of making a combined mitochondrial agent, the method comprising isolating mitochondria from cells and mixing the mitochondria with an effective amount of a therapeutic, diagnostic, or imaging agent under conditions sufficient to allow binding of the therapeutic, diagnostic, or imaging agent to the mitochondria. In some embodiments, the mitochondria are mixed with the imaging agent, and the imaging agent is 18 F-rhodamine 6G or iron oxide nanoparticles.
[0020] In another aspect, the disclosure relates to a method of making a pharmaceutical substance comprising a combined mitochondrial agent, the method comprising providing the combined mitochondrial agent and mixing the combined mitochondrial agent with a pharmaceutically acceptable carrier, such as water, saline, and respiration buffer.
[0021] In yet another aspect, the present disclosure relates to methods for treating a subject with a mitochondrial dysfunction disorder, such as Kearns-Sayre syndrome, MERRF syndrome, MELAS syndrome, Leber's disease, Barth syndrome, diabetes, or Parkinson's disease. In these methods, a therapeutically effective amount of a pharmaceutical composition containing isolated mitochondria or a combined mitochondrial agent is administered to the subject, for example, by direct injection, intravascular infusion, or by injecting the composition into the subject's blood vessels. The combined mitochondrial agent can further comprise a pharmaceutical agent.
[0022] In certain aspects of the methods described herein, the blood vessel is a blood vessel or part of the vascular system that carries blood to a target site, target organ, or target region, e.g., a coronary artery of a subject, a hepatic portal vein of a subject, a great pancreatic artery of a subject, or a prostatic artery of a subject.
[0023] In certain embodiments of the method described herein, mitochondria can have different sources, for example, mitochondria can be autologous, allogeneic, or xenogeneic.In certain embodiments, autologous mitochondria can have exogenous mtDNA.In some embodiments, mitochondria is derived from the first-degree relative of the subject.
[0024] In some embodiments, the described methods include collecting the isolated mitochondria from the cells prior to administration. The isolated mitochondria or combined mitochondrial agents can be administered to the subject immediately after the isolated mitochondria are collected from the cells.
[0025] In yet another aspect, the present disclosure relates to a method for minimizing cardiac toxicity from chemotherapy, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising isolated mitochondria and / or a combined mitochondrial agent to a subject's blood vessel. The combined mitochondrial agent can further comprise a pharmaceutical substance. In certain embodiments, the blood vessel is a coronary artery of the subject. In some cases, the subject can be treated before, during, and / or after chemotherapy treatment.
[0026] In one aspect, the present disclosure relates to a method for minimizing reperfusion injury of organs. The method comprises injecting an effective amount of isolated mitochondria or a combination of mitochondrial agents into the blood vessel of organ before (for example, immediately before), during, and / or after reperfusion injury occurs in organ. In some embodiments, organ is treated in situ or ex vivo. Isolated mitochondria and / or a combination of mitochondrial agents can be injected into organ by various routes, for example, by direct injection, by vascular infusion, and / or by injecting the composition into the blood vessel of organ. In some cases, the organ is an organ that requires high energy production, such as the brain, heart, kidney, or liver. In some other cases, the organ is a transplanted organ, such as a transplanted heart, a transplanted kidney, and a transplanted liver.
[0027] In another aspect, the present disclosure relates to a method for treating cancer in a subject.Cancer can be any type of cancer, for example, lung cancer, brain cancer, pancreatic cancer, melanoma, prostate cancer, ovarian cancer, colon cancer.In some cases, cancer is neuroblastoma (for example, pediatric neuroblastoma).The method comprises administering a therapeutically effective amount of a combined mitochondrial agent to the blood vessel of a subject with cancer.The combined mitochondrial agent can comprise a cytotoxic substance, a cytostatic substance, a growth inhibitor, or a CSF-1 inhibitor, etc.
[0028] In yet another aspect, the present disclosure relates to a method for treating a mitochondrial defect in a cell, the method comprising obtaining an effective number of mitochondria from a subject and contacting the cell with the effective number of mitochondria. The cell can be any cell with a mitochondrial defect, for example, an egg cell or embryo cell prepared during in vitro fertilization. The subject can be a male, for example, a person who provides sperm for in vitro fertilization.
[0029] In another aspect, the present disclosure relates to a method for improving mitochondrial function in a cell, the method comprising contacting the cell with isolated mitochondria and / or a combination of mitochondrial agents in an amount sufficient to improve mitochondrial function. The cell can be any type of cell known to a skilled practitioner, for example, a stem cell.
[0030] In yet another aspect, the present disclosure relates to a method for improving mitochondrial function in tissue of a subject.The method comprises administering to tissue a composition comprising isolated mitochondria and / or a combination of mitochondrial agents in an amount sufficient to improve mitochondrial function in tissue.Tissue can be any type of tissue, for example, skin tissue, facial muscle, bone marrow tissue or white adipose tissue.In some embodiments, the composition is administered to tissue by injecting the composition into tissue.
[0031] The present disclosure also provides a method for increasing blood flow or reducing vascular resistance in a subject's organ.The method comprises administering to a subject a composition comprising isolated mitochondria and / or a combination of mitochondrial agents in an amount sufficient to increase blood flow or reduce vascular resistance.The organ can be any organ, for example, heart, lung, kidney, brain, or skeletal muscle.In some embodiments, the isolated mitochondria or the combination of mitochondrial agents is administered to the subject within about 30 minutes, 40 minutes, 50 minutes, or 60 minutes from the time the mitochondrial isolation process begins.In addition, the composition can be injected into coronary artery before, during, or after cardiac surgery.In some cases, the composition is administered to a subject by injecting the composition into the blood vessel that carries blood to the organ.
[0032] In one aspect, the present disclosure provides a method for removing blockages in a subject's blood vessel.The method comprises injecting a composition comprising isolated mitochondria and / or a combination of mitochondrial agents into the blood vessel.In some cases, the subject has peripheral vascular disease.The composition is injected into the blood vessel within about 30 minutes, 40 minutes, 50 minutes, or 60 minutes from the time when the mitochondrial isolation process begins.
[0033] In another aspect, the present disclosure provides a method for transplanting cells or tissues into a subject.The method comprises the steps of contacting cells or tissues with an effective amount of a composition comprising isolated mitochondria and / or isolated mitochondrial agent; and transplanting the cells or tissues into a subject.The cells can be any type of cells, for example, stem cells, and the tissues can be any type of tissues, for example, bone marrow tissue.
[0034] In yet another aspect, the present disclosure relates to a method for improving mitochondrial function in cells or tissues. The method comprises contacting cells or tissues with an effective amount of a composition comprising isolated mitochondria and / or a combination of mitochondrial agents. In some cases, the cells are transplant cells or stem cells. In some other cases, the tissue is transplant tissue or bone marrow tissue.
[0035] The present disclosure also provides a method for treating a wound in a subject, the method comprising administering a composition comprising isolated mitochondria and / or a combined mitochondrial agent to the wound area in an amount sufficient to treat the wound.The wound can be any type of wound, for example, an open wound or a burn wound.In some cases, the composition is administered by injecting the composition into the wound tissue.
[0036] The present disclosure also relates to a method for treating a subject with metabolic disorder, the method comprises administering the composition comprising isolated mitochondria and / or combined mitochondrial agents to the white adipose tissue of the subject in an amount sufficient to treat metabolic disorder.In some embodiments, metabolic disorder is obesity or type II diabetes.The composition can be administered by injecting the composition into white adipose tissue.
[0037] In one aspect, the present disclosure provides a method for increasing mitochondrial function in a subject's white adipose tissue.The method comprises administering a composition comprising isolated mitochondria or a combination of mitochondrial agents to white adipose tissue in an amount sufficient to increase mitochondrial function.In some embodiments, the composition is administered by injecting the composition into white adipose tissue.
[0038] In yet another aspect, the present disclosure provides a method for reducing fat deposits in a subject, the method comprising administering to a fat deposit a composition comprising isolated mitochondria or a combination of mitochondrial agents in an amount sufficient to reduce fat deposits in the subject. In some embodiments, the adipose tissue is white adipose tissue.
[0039] Fat problems can be located in various places within the body, for example, under the subject's chin or in the abdomen.
[0040] The present disclosure also provides the method for treating (for example, reducing the appearance of) wrinkles or scars in an object.The method comprises administering the composition comprising isolated mitochondria and / or combined mitochondrial agent to the wrinkled or scarred area of an object in an amount sufficient to treat (for example, reduce the appearance of) wrinkles or scars.In some embodiments, the composition is administered by 28, 29, 30, 31, 32, 33 or 34 gauge hypodermic needle.
[0041] The present disclosure also relates to a method for improving mitochondrial function in the skin of an object.The method comprises administering to the object the composition comprising isolated mitochondria and / or combined mitochondrial agent in an amount sufficient to improve the mitochondrial function in the skin of the object.In some embodiments, the composition is administered by injecting the composition into skin tissue.The composition can be administered by hypodermic needle, for example, 28, 29, 30, 31, 32, 33 or 34 gauge hypodermic needle.
[0042] In one aspect, the present disclosure provides a composition comprising isolated mitochondria and / or a combined mitochondrial agent; and a carrier.In some embodiments, the composition is a pharmaceutical composition.The carrier can be any suitable carrier, for example, respiratory buffer, mitochondrial buffer, sterile mitochondrial buffer, University of Wisconsin (UW) fluid, blood, serum, or imaging agent.
[0043] In yet another aspect, the present disclosure provides a method for improving integration of transplanted cells or tissue, comprising contacting the transplanted cells or tissue with a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to improve integration of the transplanted cells or tissue.
[0044] In all of the methods and / or compositions described herein, the combined mitochondrial agent can include a pharmaceutical agent. The pharmaceutical agent can be a therapeutic agent, an imaging agent, a diagnostic agent, or any combination thereof. The imaging agent can be a radioactive agent. In some embodiments, the imaging agent is 18In some embodiments, the pharmaceutical agent is covalently linked to mitochondria. Alternatively, or additionally, the pharmaceutical agent is embedded in mitochondria. The combined mitochondrial agent can comprise an antibody or an antigen-binding fragment. Furthermore, in all methods and / or compositions described herein, mitochondria can be autologous, allogeneic, or xenogeneic. In some embodiments, mitochondria have exogenous DNA (e.g., mtDNA).
[0045] As used herein, the term "isolated mitochondria" means functional, intact mitochondria that do not contain extraneous eukaryotic cellular material.
[0046] A "combined mitochondrial agent" is an isolated mitochondrion artificially combined with a pharmaceutical, diagnostic, or imaging agent, or any other active substance. The active substance can be combined with mitochondria in any manner, for example, linked to mitochondria (e.g., chemically or electrostatically linked), attached to mitochondria, embedded in the mitochondrial membrane, substantially encapsulated within mitochondria, or completely enclosed by mitochondria, as long as the mitochondria and the active substance are in physical contact with each other. The combined mitochondrial agent is designed so that mitochondria act as a "carrier" that can transport the active substance to the patient's tissues after injection.
[0047] The terms "subject" and "patient" are used throughout this specification to describe an animal, human or non-human, to which treatment according to the methods of the present disclosure is provided. Veterinary applications are expressly contemplated by this disclosure. The terms include, but are not limited to, birds, reptiles, amphibians, and mammals, such as humans, other primates, pigs, rodents such as mice and rats, rabbits, guinea pigs, hamsters, cows, horses, cats, dogs, sheep, and goats. Preferred subjects are humans, livestock, and domestic pets such as cats and dogs.
[0048] The term "treating" is used herein to refer to delaying the onset of a condition (e.g., a disease) described herein, inhibiting, alleviating the effects of the condition, or prolonging the lifespan of a patient suffering from the condition.
[0049] "Ischemia-related disease" is a disease accompanied by ischemia. Ischemia, as used herein, is reduced blood flow to an organ and / or tissue. Reduced blood flow can be caused by any suitable mechanism, including, among others, partial or complete blockage (obstruction), narrowing (constriction), and / or leakage / rupture of one or more blood vessels that supply blood to the organ and / or tissue.
[0050] "Immediately after the mitochondria are harvested from the cells" means immediately after the mitochondria are harvested from the cells and before any significant reduction in mitochondrial viability may have occurred.
[0051] As used herein, the term "transplantation" is used throughout this specification as a general term to describe the process of implanting organs, tissues, cell masses, individual cells, or cell organelles into recipients.The term "cell transplantation" is used throughout this specification as a general term to describe the process of transferring at least one cell, for example, pancreatic islet cells or stem cells, into recipients.For example, such transplantation can be carried out by removing beta cells (or intact pancreatic islets) from the pancreas of donor and placing them into recipient patients whose pancreas cannot produce enough insulin.This term includes all categories of transplantation known in the art, except blood transfusion.Transplantation is classified according to the location and the genetic relationship between donor and recipient.This term includes, for example, autotransplantation (removal and transfer of cells or tissue from one location on a patient to the same or another location on the same subject), allotransplantation (transplantation between members of the same species), and xenotransplantation (transplantation between members of different species).
[0052] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in practicing or testing the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the event of any conflict, the present specification, including definitions, will control. Additionally, the materials, methods, and examples are merely illustrative and are not intended to be limiting.
[0053] [The present invention 1001] 1. A method for treating a subject having an ischemia-related disease, comprising administering to the subject having an ischemia-related disease a therapeutically effective amount of a composition comprising isolated mitochondria or a combined mitochondrial agent. [The present invention 1002] 1001. The method of claim 1001, wherein said composition is administered to said subject by injecting said composition into a blood vessel of said subject. [The present invention 1003] The method of any one of claims 1001 to 1002, wherein the combined mitochondrial agent comprises a therapeutic agent. [The present invention 1004] The method of any one of claims 1001 to 1002, wherein the combined mitochondrial agent comprises an imaging agent. [The present invention 1005] The method of claim 1004, wherein the imaging agent is radioactive. [The present invention 1006] Imaging materials 18 1005. The method of claim 10, wherein the compound is F-rhodamine 6G. [The present invention 1007] The method of claim 1004, wherein the imaging agent is iron oxide nanoparticles. [The present invention 1008] The method of any one of claims 1001 to 1002, wherein the ischemia-related disease is acute coronary syndrome. [The present invention 1009] The method of any one of claims 1001 to 1002, wherein the ischemia-related disease is myocardial infarction. [The present invention 1010] The method of the present invention 1009, wherein the blood vessel is a coronary artery of the subject. [The present invention 1011] The method of any one of claims 1001 to 1002, wherein the ischemia-related disease is hepatic ischemia-reperfusion injury. [The present invention 1012] The method of claim 1011, wherein the blood vessel is the hepatic portal vein of the subject. [The present invention 1013] The method of any one of claims 1001 to 1002, wherein the ischemia-related disease is ischemic injury-compartment syndrome. [The present invention 1014] The method of claim 1001 or 1002, wherein the mitochondria are autogeneic. [The present invention 1015] 1001 or 1002, wherein the mitochondria are allogeneic. [The present invention 1016] 1001 or 1002, wherein the mitochondria are xenogeneic. [The present invention 1017] The method of invention 1001 or 1002, further comprising a step of collecting the isolated mitochondria from the cells prior to the administering step, wherein the administering step comprises administering the isolated mitochondria to the subject immediately after the isolated mitochondria are collected from the cells. [The present invention 1018] 1. A method for minimizing cardiac toxicity from chemotherapy in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising isolated mitochondria or a combined mitochondrial agent before, during, or after treatment of the subject with chemotherapy. [The present invention 1019] The method of claim 1018, wherein the composition is administered to the subject by injecting the composition into a blood vessel of the subject. [The present invention 1020] The method of claim 1018, wherein the combined mitochondrial agent comprises a pharmaceutical agent. [The present invention 1021] The method of claim 1019, wherein the blood vessel is a coronary artery of the subject. [The present invention 1022] 1. A method for delivering an agent to a target site in a subject, comprising administering a therapeutically effective amount of a combined mitochondrial agent to a blood vessel of the subject. [The present invention 1023] The method of claim 1022, wherein the target site is the heart, kidney, pancreas, lung, optic nerve, brain, or skeletal muscle of the subject. [The present invention 1024] The method of claim 1022, wherein said blood vessel is part of a subject's vascular system that carries blood to a target site. [The present invention 1025] The method of claim 1022, wherein the combined mitochondrial agent comprises a pharmaceutical agent covalently linked to the mitochondria. [The present invention 1026] The method of claim 1022, wherein the combined mitochondrial agent comprises a pharmaceutical agent embedded in the mitochondria. [The present invention 1027] The method of claim 1022, wherein the combined mitochondrial agent comprises a therapeutic agent. [The present invention 1028] The method of claim 1022, wherein the combined mitochondrial agent comprises a diagnostic agent. [The present invention 1029] The method of claim 1022, wherein the combined mitochondrial agent comprises an antibody or antigen-binding fragment. [The present invention 1030] 1. A method of imaging tissue of a subject, the method comprising: a) administering to said subject an effective amount of a combined mitochondrial agent comprising an imaging agent; and b) imaging said tissue of said subject with an imaging technique. [The present invention 1031] Imaging materials 18 1030. The method of claim 10, wherein the F-labeled rhodamine 6G. [The present invention 1032] The method of claim 1030, wherein the imaging agent is iron oxide magnetic nanoparticles. [The present invention 1033] 1. A method of making a combined mitochondrial agent, comprising: 1) isolating mitochondria from cells; 2) mixing the mitochondria with an effective amount of a therapeutic, diagnostic, or imaging agent under conditions sufficient to allow binding of the therapeutic, diagnostic, or imaging agent to the mitochondria. [The present invention 1034] The mitochondria are mixed with an imaging agent, and the imaging agent is 18 1033. The method of claim 1033, wherein the compound is F-rhodamine 6G. [This invention 1035] The method of claim 1033, wherein the mitochondria are mixed with an imaging agent, and the imaging agent is iron oxide nanoparticles. [The present invention 1036] 1. A method of making a pharmaceutical substance comprising a combined mitochondrial agent, the method comprising: Providing a combined mitochondrial agent; and mixing the combined mitochondrial agents with a pharmaceutically acceptable carrier. [This invention 1037] The method of claim 1036, wherein the pharmaceutically acceptable carrier is a respiratory buffer. [The present invention 1038] 1. A method for treating a mitochondrial dysfunction disorder in a subject, comprising administering to a subject having a mitochondrial dysfunction disorder a therapeutically effective amount of a pharmaceutical composition comprising isolated mitochondria or a combined mitochondrial agent. [This invention 1039] The method of claim 1038, wherein the composition is administered to the subject by injecting the composition into a blood vessel of the subject. [The present invention 1040] The method of any one of claims 1038 to 1039, wherein the mitochondrial dysfunction disorder is Kearns-Sayre syndrome, MERRF syndrome, MELAS syndrome, or Leber's disease. [The present invention 1041] The method of any one of claims 1038 to 1039, wherein the mitochondrial dysfunction disorder is Barth syndrome. [The present invention 1042] The method of any one of claims 1038 to 1039, wherein the mitochondrial dysfunction disorder is diabetes. [This invention 1043] The method of claim 1042, wherein the blood vessel is the great pancreatic artery of the subject. [This invention 1044] 1039. The method of any one of claims 1038 to 1039, wherein the mitochondrial dysfunction disorder is Parkinson's disease. [This invention 1045] 1039. The method of any one of claims 1038 to 1039, wherein said pharmaceutical composition comprises a combined mitochondrial agent comprising a pharmaceutical agent. [The present invention 1046] The method of any one of claims 1038 to 1039, wherein the mitochondria are autologous. [This invention 1047] The method of claim 1046, wherein the autologous mitochondria have exogenous mtDNA. [This invention 1048] 1039. The method of claim 1038 or 1039, wherein the mitochondria are of homologous origin. [This invention 1049] The method of any one of claims 1038 to 1039, wherein the mitochondria are from a first-degree relative of the subject. [The present invention 1050] 1039. The method of claim 1038 or 1039, wherein the mitochondria are of heterologous origin. [This invention 1051] 1. A method for minimizing reperfusion injury in an organ, comprising injecting an effective amount of isolated mitochondria or a combined mitochondrial agent into the blood vessels of the organ before, during, or after reperfusion injury occurs in the organ. [This invention 1052] The method of claim 1051, wherein the organ is treated in situ or ex vivo. [This invention 1053] The method of claim 1051, wherein the organ is a transplant organ. [This invention 1054] The method of claim 1051, wherein the organ is the brain. [This invention 1055] The method of claim 1051, wherein the organ is the heart. [The present invention 1056] The method of claim 1051, wherein the organ is a kidney. [This invention 1057] 1. A method of treating cancer in a subject, comprising administering a therapeutically effective amount of a combined mitochondrial agent to a blood vessel of a subject having cancer, wherein the combined mitochondrial agent comprises a cytotoxic agent. [This invention 1058] The method of claim 1057, wherein the cancer is prostate cancer, ovarian cancer, or neuroblastoma. [This invention 1059] 1057. The method of claim 1057, wherein said blood vessel is a prostatic artery of the subject. [The present invention 1060] 1. A method of treating mitochondrial defects in egg or embryo cells, the method comprising: 1) obtaining an effective number of mitochondria from a subject; and 2) contacting said cells with said effective number of mitochondria. [The present invention 1061] The method of claim 1060, wherein the egg cells are prepared for in vitro fertilization. [The present invention 1062] The method of claim 1060, wherein the embryonic cells are prepared during in vitro fertilization. [The present invention 1063] The method of claim 1060, wherein the subject is a male who provides sperm for in vitro fertilization. [This invention 1064] 1. A method for improving mitochondrial function in a cell, comprising contacting the cell with isolated mitochondria or a combined mitochondrial agent in an amount sufficient to improve mitochondrial function in the cell. [This invention 1065] The method of claim 1064, wherein the cell is a stem cell. [The present invention 1066] 1. A method for improving mitochondrial function in a tissue of a subject, comprising administering to the tissue a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to improve mitochondrial function in the tissue. [This invention 1067] 106. The method of claim 1066, wherein said tissue is skin tissue, facial muscle, bone marrow tissue, or white adipose tissue. [The present invention 1068] The method of claim 1066, wherein said composition is administered to said tissue by injecting said composition into said tissue. [The present invention 1069] 1. A method of increasing blood flow or decreasing vascular resistance in an organ of a subject, the method comprising: Administering a composition comprising isolated mitochondria or combined mitochondrial agents to the subject in an amount sufficient to increase blood flow or decrease vascular resistance. [The present invention 1070] 1069. The method of claim 1069, wherein the organ is a heart, lung, kidney, brain, or skeletal muscle. [This invention 1071] The method of claim 1069, wherein the isolated mitochondria or the combined mitochondrial agents are administered to the subject within 30, 40, 50, or 60 minutes from the time the mitochondrial isolation process begins. [This invention 1072] 1069. The method of claim 1069, wherein said composition is injected into a coronary artery before, during, or after cardiac surgery. [This invention 1073] 1069. The method of claim 1069, wherein the composition is administered to the subject by injecting the composition into a blood vessel that carries blood to the organ. [This invention 1074] 1. A method of removing a blockage in a blood vessel in a subject, comprising injecting into said blood vessel a composition comprising isolated mitochondria or a combined mitochondrial agent. [This invention 1075] The method of claim 1074, wherein the subject has peripheral vascular disease. [This invention 1076] 1074. The method of claim 1074, wherein said composition is injected into a blood vessel within about 30, 40, 50, or 60 minutes from the time the mitochondrial isolation process begins. [This invention 1077] 1. A method of transplanting cells or tissue into a subject, the method comprising: contacting the cells or tissue with an effective amount of a composition comprising isolated mitochondria or an isolated mitochondrial agent; and Transplanting said cells or said tissue into said subject. [This invention 1078] The method of claim 1077, wherein the cell is a stem cell. [This invention 1079] The method of claim 1077, wherein the tissue is bone marrow. [The present invention 1080] 1. A method for improving mitochondrial function in a cell or tissue, comprising contacting the cell or tissue with an effective amount of a composition comprising isolated mitochondria or a combined mitochondrial agent, thereby improving mitochondrial function in the cell or tissue. [This invention 1081] The method of claim 1080, wherein the cells are transplant cells. [This invention 1082] The method of claim 1080, wherein the cell is a stem cell. [This invention 1083] The method of claim 1080, wherein the tissue is a transplant tissue. [This invention 1084] The method of claim 1080, wherein the tissue is bone marrow tissue. [This invention 1085] 1. A method of treating a wound in a subject, comprising administering to the subject an area of the wound a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to treat the wound. [The present invention 1086] The method of claim 1085, wherein the wound is an open wound or a burn wound. [This invention 1087] The method of claim 1085, wherein the composition is administered by injecting the composition into the wound tissue. [This invention 1088] 1. A method of treating a subject having a metabolic disorder, comprising administering to white adipose tissue of the subject a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to treat the metabolic disorder. [This invention 1089] The method of claim 1088, wherein the metabolic disorder is obesity or type II diabetes. [The present invention 1090] The method of claim 1088, wherein the composition is administered by injecting the composition into white adipose tissue. [This invention 1091] A method for increasing mitochondrial function in a subject's white adipose tissue, comprising administering to the white adipose tissue a composition comprising isolated mitochondria or a combination of mitochondrial agents in an amount sufficient to increase mitochondrial function. [This invention 1092] 1091. The method of claim 1091, wherein the composition is administered by injecting the composition into white adipose tissue. [This invention 1093] 1. A method for reducing fat deposits in a subject, comprising administering to the fat deposits a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to reduce fat deposits in the subject. [This invention 1094] The method of claim 1093, wherein the adipose tissue is white adipose tissue. [This invention 1095] The method of the present invention 1093, wherein the fat problem is located under the chin or in the abdomen of the subject. [This invention 1096] 1. A method for treating skin wrinkles or scars in a subject, comprising administering to an area of the skin wrinkle or scar a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to treat the skin wrinkle or scar. [This invention 1097] 1096. The method of claim 1096, wherein said composition is administered by a 28, 29, 30, 31, 32, 33, or 34 gauge hypodermic needle. [This invention 1098] 1. A method for improving mitochondrial function in the skin of a subject, comprising administering to the subject a composition comprising isolated mitochondria or combined mitochondrial agents in an amount sufficient to improve mitochondrial function in the skin of the subject. [This invention 1099] The method of claim 1098, wherein the composition is administered by injecting the composition into skin tissue. [The present invention 1100] The method of claim 1098, wherein the composition is administered by a 28, 29, 30, 31, 32, 33, or 34 gauge hypodermic needle. [The present invention 1101] Isolated mitochondria or combined mitochondrial agents; and Carrier A composition comprising: [The present invention 1102] The composition of the present invention 1101, which is a pharmaceutical composition. [The present invention 1103] The composition of any one of claims 1101 to 1102, wherein the combined mitochondrial agent comprises a therapeutic agent. [The present invention 1104] The composition of any one of claims 1101 to 1102, wherein the combined mitochondrial agent comprises an imaging agent. [This invention 1105] The composition of claim 1104, wherein the imaging agent is radioactive. [The present invention 1106] The imaging material is 18 1104. The composition of the present invention, which is F-rhodamine 6G or iron oxide nanoparticles. [This invention 1107] The composition of any one of claims 1101 to 1102, wherein the combined mitochondrial agent comprises a diagnostic agent. [This invention 1108] The composition of any one of claims 1101 to 1102, wherein the combined mitochondrial agent comprises a pharmaceutical agent covalently linked to the mitochondria. [This invention 1109] The composition of any one of claims 1101 to 1102, wherein the combined mitochondrial agent comprises a pharmaceutical agent embedded in mitochondria. [The present invention 1110] The composition of any one of claims 1101 to 1102, wherein the combined mitochondrial agent comprises an antibody or antigen-binding fragment. [The present invention 1111] The composition of invention 1101 or 1102, wherein the mitochondria are autologous, allogeneic, or xenogeneic. [The present invention 1112] The composition of claim 1101 or 1102, wherein the mitochondria carry exogenous DNA. [The present invention 1113] The composition of claim 1101 or 1102, wherein the carrier is a respiratory buffer or a mitochondrial buffer. [This invention 1114] The composition of any one of claims 1101 to 1102, wherein the carrier is University of Wisconsin (UW) fluid. [This invention 1115] The composition of claim 1101 or 1102, wherein the carrier is blood or serum. [The present invention 1116] 1101 or 1102, wherein the carrier is an imaging agent. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims. [Brief explanation of the drawings]
[0054] [Figure 1] FIG. 1 is a schematic diagram of one exemplary protocol for isolating mitochondria from tissue or cultured cells. [Figure 2] Figure 2A is a series of images of a rabbit heart undergoing focal ischemia, injected with 1 × 10 double-labeled mitochondria at the onset of reperfusion. The top row displays volume renderings of the heart. Micro-computed tomography (μCT), positron emission tomography (PET), and composite renderings are shown from left to right. The middle row shows a single coronary slice of the heart. Magnetic resonance imaging (MRI), PET, and composite images are depicted from left to right. The bottom row of images is a single transverse slice of the injected heart. MRI, PET, and composite images are depicted from left to right. Figure 2B is a series of images of a rabbit heart undergoing focal ischemia, perfused with 1 × 10 double-labeled mitochondria at the onset of reperfusion. The top row displays volume renderings of the heart, with μCT, PET, and composite renderings shown from left to right. The middle row shows a single coronary slice of the heart, with MRI, PET, and composite images depicted from left to right. The bottom row shows a single transverse slice of the perfused heart. MRI, PET, and merged images are shown from left to right. [Figure 3]Figure 3A is a series of images showing histological staining of an ischemic heart injected with human mitochondria. The injected heart sections were immunofluorescently stained for desmin (green) and the human-specific mitochondrial marker MTC02 (red, human-specific anti-mitochondrial mouse monoclonal antibody [MTC02] (ab80649, Abcam, Cambridge, MA)) (top row). The middle row shows staining with wheat germ agglutinin (red) and the human-specific mitochondrial marker 113-1 (green) (anti-mitochondrial antibody [113-1] (ab92824)). Nuclei are identified using the DNA-binding dye 4,6-diamidino-2-phenylindole (DAPI) (blue). MTC02 and nuclear staining are shown using phase-contrast illumination (bottom row). Transplanted mitochondria associated with the cardiomyocyte membrane are indicated by arrows. Figure 3B is a series of images showing histological staining of an ischemic heart perfused with human mitochondria. Perfused hearts were immunostained with α-actinin (red) and MTC02 (green, human-specific anti-mitochondrial mouse monoclonal antibody [MTC02] (ab80649, Abcam, Cambridge, MA)) (top row). Transplanted mitochondria are indicated by arrows. Some hearts were perfused with lectin and subsequently fixed to reveal the luminal vascular surface. The right-center row shows lectin (green) and 113-1 (red) staining; whereas the bottom row shows Prussian blue staining for iron (blue) and pararosaniline counterstaining (pink). [Figure 4] Schematic showing quantification of area at risk (using Monastryl blue pigment) and infarct size (using triphenyltetrazolium chloride (TTC) staining) in control focally ischemic hearts (n=3) and those perfused with 1×108 autologous liver mitochondria (n=3). [Figure 5] FIG. 1 is a schematic diagram showing regional myocardial function in the ischemic region assessed by segmental systolic shortening using three piezoelectric ultrasound transducers. [Figure 6]Figure 6A is a super-resolution structured illumination microscopy (SR-SIM) red channel image showing mitochondrial internalization and fusion in human cardiomyocytes. Figure 6B is a SR-SIM green channel image showing mitochondrial internalization and fusion in human cardiomyocytes. Figure 6C is a SR-SIM blue channel image showing mitochondrial internalization and fusion in human cardiomyocytes. Figure 6D is a SR-SIM composite image showing mitochondrial internalization and fusion in human cardiomyocytes. [Figure 7] Figure 7A is a graph showing the results of flow cytometry for mitochondria in the control group, Figure 7B is a graph showing the results of flow cytometry for green fluorescent protein (GFP)-labeled mitochondria, Figure 7C is a graph showing the results of flow cytometry for red fluorescent protein (RFP)-labeled mitochondria, and Figure 7D is a graph showing the results of flow cytometry for mitochondria isolated from iCell® cardiomyocytes treated with GFP-labeled mitochondria. [Figure 8] FIG. 1 is a schematic diagram showing a proposed model of the endosomal pathway for mitochondrial internalization. [Figure 9] FIG. 1 is a diagram showing the experimental protocol to demonstrate that injected mitochondria do not obstruct coronary blood flow. [Figure 10] Figure 10A is an electrocardiogram (ECG) tracing graph showing a baseline ECG and an ECG after a pig model was treated with adenosine, vasopressin, and epinephrine. Figure 10B is an ECG tracing graph showing an ECG after a pig model was treated with vehicle and mitochondria. Figure 10C is an ECG tracing graph showing an ECG after a pig model was treated with 3 um, 10 um, and 150 um polystyrene beads. [Figure 11]Figure 11A is a bar graph showing baseline QRS and QRS after treatment of a pig model with adenosine, vasopressin, epinephrine, mitochondria, and vehicle. Figure 11B is a bar graph showing baseline corrected QT (cQT) intervals and cQT intervals after treatment of a pig model with adenosine, vasopressin, epinephrine, mitochondria, and vehicle. Figure 11C is a bar graph showing baseline QRS and QRS after treatment of a pig model with 3 um, 10 um, and 150 um polystyrene beads and mitochondria. Figure 11D is a bar graph showing baseline cQT intervals and cQT intervals after treatment of a pig model with 3 um, 10 um, and 150 um polystyrene beads and mitochondria. [Figure 12] Figure 12A is a bar graph showing the percentage of systolic shortening after coronary injection of vehicle, adenosine, epinephrine, vasopressin, and mitochondria. Figure 12B is a bar graph showing the percentage of systolic shortening after coronary injection of 3 um, 10 um, and 150 um polystyrene beads and mitochondria. [Figure 13] Figure 13A is a bar graph showing coronary blood flow after coronary injection of vehicle, adenosine, vasopressin, and mitochondria. Figure 13B is a bar graph showing coronary blood flow after coronary injection of mitochondria, devitalized mitochondria, and 3 um, 10 um, and 150 um polystyrene beads. [Figure 14] Graph showing coronary blood flow at different time points after coronary injection of adenosine, vasopressin, mitochondria, and devitalized mitochondria (mitochondria 1 x 10 organelles / ml; adenosine 60 ug; vasopressin 1 U; devitalized mitochondria 1 x 10 organelles / ml; baseline = 20 ml / min; values are mean ± SE). [Figure 15] Figure 15A is a bar graph showing coronary blood flow in response to different doses of mitochondria, and Figure 15B is a graph showing coronary blood flow at different time points in response to different doses of mitochondria. [Figure 16]FIG. 1 is a diagram showing how cardioprotection conferred by intravascular injection of mitochondria in a large animal model (pig) was demonstrated. [Figure 17] Figure 17A is a series of graphs showing left ventricular end-diastolic pressure (LVEDP) and dP / dt of left ventricular pressure following vascular infusion of mitochondria, and Figure 17B is a series of graphs showing percentage systolic shortening following vascular infusion of mitochondria. [Figure 18] Figure 18A is a graph showing the percentage of area at risk in the left ventricle following vascular injection of vehicle and following vascular injection of mitochondria, and Figure 18B is a graph showing the percentage of infarct size in the area at risk following vascular injection of vehicle and following vascular injection of mitochondria. [Figure 19] Figure 19A is a bar graph showing the number of spots in mice receiving single or multiple injections of autologous mitochondria and single or multiple injections of splenocytes, and Figure 19B is a bar graph showing the number of spots in mice receiving single or multiple injections of allogeneic mitochondria and single or multiple injections of splenocytes. [Figure 20] Graph showing the percentage of alloantibodies in response to single and multiple injections of autologous and allogeneic mitochondria, and single and multiple injections of splenocytes. [Figure 21] 1 is a diagram showing the protocol for determining the optimal concentration of rhodamine 6G, incubation time, and temperature for mitochondrial uptake of rhodamine 6G. [Figure 22] Figure 22A is a bar graph showing the concentration of rhodamine 6G in the unbound fraction under different incubation conditions (4°C) and Figure 22B is a bar graph showing the concentration of rhodamine 6G in the unbound fraction under different incubation conditions (26°C). [Figure 23] Figure 23A is a bar graph showing the concentration of rhodamine 6G in the bound fraction under different incubation conditions (4°C) and Figure 23B is a bar graph showing the concentration of rhodamine 6G in the bound fraction under different incubation conditions (26°C). [Figure 24]Figure 24A is a bar graph showing the concentration of rhodamine 6G in the bound fraction after incubating mitochondria with 2.5 uM rhodamine 6G under different incubation conditions, and Figure 24B is a bar graph showing the concentration of rhodamine 6G in the bound fraction after incubating mitochondria with 2.5 uM rhodamine 6G under different incubation conditions. [Figure 25] Figure 25A is a bar graph showing the concentration of rhodamine 6G in the bound fraction after incubating mitochondria with 1.25 uM rhodamine 6G under different incubation conditions. Figure 25B is a bar graph showing the concentration of rhodamine 6G in the bound fraction after incubating mitochondria with 1.25 uM rhodamine 6G under different incubation conditions. [Figure 26] FIG. 1 is a schematic diagram showing adoptive mitochondrial transfer into human endothelial colony forming cells (ECFCs). [Figure 27] Figure 27A is a schematic diagram showing an in vivo angiogenesis assay, and Figure 27B is a series of macroscopic images showing explants harvested 7 days after implantation. [Figure 28] Figure 28A shows two hematoxylin and eosin (H&E) stained images showing that red blood cell-filled vessels were abundant in implants containing ECFC-mitochondria (ECFC-Mito) but not in implants containing the ECFC control. Figure 28B shows a graph showing quantification of microvessel density, revealing higher vessel density in implants containing ECFC-Mito than in implants containing the ECFC control. [Figure 29] Figure 29A is an image showing the binding of rhodamine-conjugated UEA-1 lectin in the lumen of newly formed perfused blood vessels, and Figure 29B is an image of human-specific CD31 (h-CD31) immunostaining of the lumen of newly formed perfused blood vessels. [Figure 30]Figure 30A is a PET / CT image showing the distribution of mitochondria in both the left and right lungs after injection of 18F-rhodamine 6G-labeled mitochondria into the main pulmonary artery. Figure 30B is a PET / CT image showing the distribution of mitochondria in both the left and right lungs after injection of 18F-rhodamine 6G-labeled mitochondria into the main pulmonary artery. [Figure 31] Figure 31A is a photograph showing pulmonary ischemia / reperfusion injury without mitochondrial treatment, and Figure 31B is a photograph showing pulmonary ischemia / reperfusion injury with mitochondrial treatment. [Figure 32] PET / CT images showing mitochondria located in the optic nerve after injection of 18F-rhodamine 6G-labeled mitochondria into the common carotid artery of a mouse. [Figure 33] FIG. 1 is a schematic diagram illustrating cardiac segmentation. DETAILED DESCRIPTION OF THE INVENTION
[0055] Detailed Description The present invention is based, at least in part, on the discovery that isolated mitochondria, as well as isolated mitochondria linked to therapeutic, diagnostic, and / or imaging agents, can be delivered to a patient's tissues by injecting them into the patient's blood vessels. A skilled practitioner can use relatively simple medical procedures to distribute mitochondria locally and / or globally to a patient's tissues and / or cells for various purposes. Furthermore, mitochondria can be used as a carrier substance to deliver, for example, therapeutic, diagnostic, and / or imaging agents to a patient's tissues. It is further noted that, compared to some conventional nanoparticle-based therapeutic regimens, mitochondria are non-toxic and do not induce any substantial adverse immune or autoimmune responses.
[0056] Without being bound by any theory, it is believed that injected mitochondria extravasate through the capillary wall by first adhering to the endothelium. After they are injected or infused into an artery, mitochondria can cross the vascular endothelium and be taken up by tissue cells via an endosomal actin-dependent internalization process.
[0057] Combined mitochondrial agents A combined mitochondrial agent includes mitochondria physically associated with an agent, such as a therapeutic, diagnostic, and / or imaging agent.
[0058] A therapeutic agent can be any agent with therapeutic or prophylactic use. Exemplary therapeutic agents include, for example, therapeutic agents for ischemia-related disorders and cytotoxic agents for treating cancer, among others. In some cases, mitochondria can deliver therapeutic agents to specific cells, such as tumor cells. A therapeutic agent can be, for example, an intracellular inhibitor, inactivator, toxin, restrictor, and / or cytostatic / cytotoxic agent that, once inside the cell, inhibits, destroys, restricts, modifies, and / or alters the cell so that it can no longer function normally and / or survive. A therapeutic agent can be, for example, an agent that restores proper function of a cell, such as a DNA vector for gene therapy. A therapeutic agent can be, for example, an inorganic or organic compound; a small molecule (less than 500 daltons) or a macromolecule; a proteinaceous molecule, such as a peptide, polypeptide, protein, post-translationally modified protein, or antibody; or a nucleic acid molecule, such as a double-stranded DNA, a single-stranded DNA, a double-stranded RNA, a single-stranded RNA, or a triple-helical nucleic acid molecule. In some embodiments, the therapeutic agent can be a natural product derived from any known organism (e.g., from an animal, plant, bacterium, fungus, protist, or virus) or derived from a library of synthetic molecules. In some embodiments, the therapeutic agent can be a monomeric compound or a polymeric compound. Some exemplary therapeutic agents include cytotoxic agents, DNA vectors, small interfering RNA (siRNA), microRNA (miRNA), reactive peptides, nanoparticles, microspheres, and fluorescent molecules.
[0059] A diagnostic agent is an agent that has diagnostic use. Because mitochondria deliver diagnostic agents into cells, in some embodiments, diagnostic agents can be designed to measure intracellular conditions, such as intracellular pH and oxidative stress.
[0060] Imaging agents are agents employed in imaging techniques. Such techniques or modalities include, but are not limited to, X-ray, computed tomography (CT), magnetic resonance imaging (MRI), scintigraphy, fluorescence, ultrasound, etc. Imaging agents can be fluorescent and / or radioactive. In some embodiments, imaging agents can also be diagnostic agents. Exemplary imaging agents include MitoTracker fluorophores (Thermo Fisher Scientific Inc.), CellLight® RFP, BacMam 2.0 (Thermo Fisher Scientific Inc.), pH-sensitive pHrodo fluorescent dyes (Thermo Fisher Scientific Inc.), 18 F-rhodamine 6G, 18 These include, but are not limited to, F-labeled rhodamine B, magnetic iron oxide nanoparticles, and gold- and platinum-based nanoparticles.
[0061] As discussed above, the combined mitochondrial agent comprises mitochondria and an active substance that are in direct and / or indirect physical contact with each other. For example, the active substance can be linked to mitochondria, attached to mitochondria, embedded in the mitochondrial membrane, or completely or partially encapsulated in mitochondria. In some cases, the pharmaceutical substance can be linked to mitochondria by a covalent bond. In some cases, the active substance is linked to a component of the mitochondrial membrane directly by a covalent bond (e.g., a carboxamide bond and a disulfide bond) or indirectly by a linker (e.g., a peptide linker) or another covalently bound active substance. In other cases, the active substance can be linked to mitochondria by a non-covalent bond, for example, through hydrophobic interaction, van der Waals interaction, and / or electrostatic interaction, etc.
[0062] In some embodiments, the combined mitochondrial agents can include two or more different types of agents, e.g., two different kinds of therapeutic agents, three different kinds of imaging agents, one therapeutic agent and one imaging agent, a therapeutic agent and a diagnostic agent, etc. The skilled practitioner will recognize that any variations are possible.
[0063] One particularly useful linker that connects mitochondria and active substance provides the sustained release of the active substance after injection.This can be achieved, for example, by using hydrazone functional group.For example, hydrazone is formed so that active substance is covalently bound to the component on mitochondrial membrane.Once this combined mitochondrial agent is taken into cells, pH change will cause hydrazone hydrolysis, and the linked active substance will be released into cells.
[0064] In some embodiments, therapeutic, diagnostic, and / or imaging agents can be linked to the outer mitochondrial membrane using functionalized surface chemistry. In some cases, heterobifunctional chemistry can link therapeutic, diagnostic, and / or imaging agents to the mitochondrial surface, and once internalized, these agents can be released via interaction with intracellular esterases (e.g., via interaction with acetoxymethyl esters) or by UV or near-infrared light activation strategies. UV light activation and near-infrared light activation strategies are described, for example, in Zhou, Fang, Hanjie Wang, and Jin Chang, "Progress in the Field of Constructing Near-Infrared Light-Responsive Drug Delivery Platforms," Journal of Nanoscience and Nanotechnology 16.3(2016): 2111-2125; Bansal, Akshaya, and Yong Zhang, "Photocontrolled nanoparticle delivery systems for biomedical applications," Accounts of chemical research 47.10(2014): 3052-3060; Barhoumi, Aoune, Qian Liu, and Daniel S. Kohane, "Ultraviolet light-mediated drug delivery: Principles, applications, and challenges," Journal of Controlled Release 219(2015): 31-42. Each of these is incorporated by reference in its entirety.
[0065] Pharmaceutical and Other Compositions The present disclosure provides compositions comprising isolated mitochondria, compositions comprising combined mitochondrial agents, compositions comprising both isolated mitochondria and combined mitochondrial agents, and methods of using such compositions.
[0066] The pharmaceutical compositions described herein may comprise mitochondria and / or a combination of mitochondrial agents and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" includes saline, solvents, dispersion media, coating agents, antibacterial and antifungal agents, isotonic and absorption-delaying agents, etc., that are compatible with pharmaceutical administration. In some embodiments, the pharmaceutically acceptable carrier is phosphate buffered saline, saline, Krebs buffer, Tyrode's solution, contrast agent, or Omnipaque, or a mixture thereof. In some embodiments, the pharmaceutically acceptable carrier is sterile mitochondrial buffer (300 mM sucrose; 10 mM K+-HEPES (potassium buffered (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.2); 1 mM K+-EGTA, (potassium buffered ethylene glycol tetraacetic acid, pH 8.0)). In some embodiments, the pharmaceutically acceptable carrier is respiration buffer (250 mM sucrose, 2 mM KH2PO4, 10 mM MgCl2, 20 mM K-HEPES buffer (pH 7.2), and 0.5 mM K-EGTA (pH 8.0).
[0067] A pharmaceutical composition is typically formulated to be compatible with its intended route of administration, examples of which include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), sublingual, transdermal (e.g., topical), transmucosal, and rectal administration.
[0068] Pharmaceutical compositions can be formulated for various clinical uses, such as imaging, wound treatment, injury treatment, organ preservation, improving mitochondrial function in organs or tissues, and skin healing. In some cases, the pharmaceutically acceptable carrier is a contrast agent for imaging purposes. In some embodiments, the pharmaceutical composition may include antiseptics, antibacterial agents (e.g., antibiotics), antifungal agents, disinfectants, analgesics, anesthetics, steroids, nutritional supplements, ethereal oils, etc. Anesthetics are drugs that can suppress pain during surgery or treatment. Exemplary analgesics include, but are not limited to, paracetamol, nonsteroidal anti-inflammatory drugs, salicylates, ibuprofen, and lidocaine. Exemplary antibacterial agents include, but are not limited to, dichlorobenzyl alcohol, amylmetacresol, and antibiotics. Exemplary antibiotics include penicillins, carbapenems, cephalosporins, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, antifolates, sulfonamides, trimethoprim, pyrimethamine, nitrofurans, methenamine mandelate, methenamine hippurate, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid, cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone, and viomycin. Antiseptics are antibacterial substances that can be applied to live tissue / skin to reduce the possibility of infection, sepsis, or decay. Exemplary antiseptics include, but are not limited to, chlorhexidine and its salts, benzalkonium and its salts, triclosan, and cetylpyridium chloride. Exemplary antifungal agents include, but are not limited to, tolnaftate, miconazole, fluconazole, clotrimazole, econazole, ketoconazole, itraconazole, terbinafine, amphotericin, nystatin, and natamycin.Exemplary steroidal agents include, but are not limited to, prednisone acetate, prednisolone valerate, prednisolone, alclometasone dipropionate, fluocinolone acetonide, dexamethasone, methylprednisolone, desonide, pivolate, clocortolone pivolate, triamcinolone acetonide, prednicarbate, fluticasone propionate, flurandrenolide, mometasone furoate, desoximetasone, betamethasone, betamethasone dipropionate, betamethasone valerate, betamethasone propionate, betamethasone benzoate, diflorasone diacetate, fluocinonide, halcinonide, amcinonide, halobetasol propionate, and clobetasol propionate. Exemplary nutritional supplements include, but are not limited to, vitamins, minerals, herbal products, and amino acids. Vitamins include, but are not limited to, vitamin A, vitamins in the vitamin B family, vitamin C, vitamins in the vitamin D family, vitamin E, and vitamin K. Ethereal oils include, but are not limited to, those derived from mint, sage, fir, lavender, basil, lemon, juniper, rosemary, eucalyptus, marigold, chamomile, orange, etc. Many of these agents are described, for example, in WO2008152626, which is incorporated by reference in its entirety.
[0069] Compositions containing mitochondria and / or combined mitochondrial agents can be formulated in any form, e.g., liquid, semi-solid, or solid. Exemplary compositions include solutions, creams, ointments, salves, oils, emulsions, liposomal formulations, among others.
[0070] Compositions for transplantation Isolated mitochondria or combined mitochondrial agents can be included in compositions designed for use in organ, tissue, or cell transplantation.The composition can comprise isolated mitochondria and / or combined mitochondrial agents and a liquid suitable for in situ or ex vivo administration to patients and / or organs, for example, to maintain organs, tissues, or cells ex vivo.Generally, the liquid will be an aqueous solution.Examples of solutions include phosphate-buffered saline (PBS), Celsior™ solution, Perfadex™ solution, Collins' solution, citrate solution, tissue culture medium (e.g., Dulbecco's modified Eagle's medium (DMEM)), histidine-tryptophan-ketoglutarate (HTK) solution, and University of Wisconsin (UW) solution (Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994).
[0071] The University of Wisconsin Cold Preservation Solution is considered the standard solution for organ transplantation. It contains the following: 100 mM potassium lactobionate, 25 mM KH2PO4, 5 mM MgSO4, 30 mM raffinose, 5 mM adenosine, 3 mM glutathione, 1 mM allopurinol, and 50 g / L hydroxyethyl starch. Isolated mitochondria or combined mitochondrial agents can be added to these fluids for organ, tissue, and cell preservation.
[0072] blood products Mitochondria and / or combined mitochondrial agents can be included in a composition comprising blood and / or blood-derived products. In some embodiments, the composition can comprise mitochondria and / or mitochondrial agents and blood, for example, whole blood, serum, one or more individual blood components, and / or artificial blood substitutes. In some cases, these blood products can be administered to a subject, and the mitochondria in the blood products can improve mitochondrial function in the subject. For example, such blood products can be administered to a patient as part of a transfusion procedure. As known in the art, blood or blood products can be stored in any number of containers, for example, blood bags, ampoules, and / or vials.
[0073] Skin and cosmetic compositions The isolated mitochondria and / or combined mitochondrial agents can be included in a composition that can be applied to the skin and / or to wounds in the skin (e.g., burns, small cuts, larger lacerations, necrotic areas, areas damaged by bacterial, fungal, or viral infections, or areas with damage caused by inflammation, e.g., rashes), wrinkles, or scars (e.g., topically and / or by injection). The composition can also include any known agent that can be used in dermatological or cosmetic products, such as abrasives, antiseptics, antibacterial agents (e.g., antibiotics), antifungals, disinfectants, analgesics, anesthetics, steroids, nutritional supplements, and / or ethereal oils.
[0074] Skilled practitioners will recognize that for topical compositions, such as compositions of liquid, cream, lotion, ointment, or oil, an abrasive can be added to the composition to help deliver mitochondria and / or combined mitochondrial agents to the underlying layers of skin cells after application (for example, when the composition is rubbed into the skin and / or painted on).Abrasives are materials used to wear away tissue (for example, damaged or dead skin cells) through friction.Compositions comprising abrasives and isolated mitochondria or combined mitochondrial agents can be used for various purposes, such as cosmetic use, treating wounds, etc.Some abrasives are described, for example, in U.S. Patent No. 5,830,445, U.S. Patent No. 2,561,043, and U.S. Patent No. 4,279,890, each of which is incorporated by reference in its entirety. The skilled practitioner will also recognize that any agent or composition known in the art that aids in the transport of compounds into the lower layers of the skin and / or into the pores of the skin may be useful in such embodiments, and that said agent or composition may be included in a composition that includes mitochondria and / or a mitochondrial agent, or may be applied to the patient separately but in conjunction with said composition.
[0075] Methods of Making Compositions Comprising Mitochondria and / or Combined Mitochondrial Agents Isolation of mitochondria Mitochondria for use in the methods described herein can be isolated or provided from any source, for example, isolated from cultured cells or tissue.Exemplary cells include, but are not limited to, muscle tissue cells, cardiac fibroblasts, cultured cells, HeLa cells, prostate cancer cells, yeast, and any mixture thereof.Exemplary tissues include, but are not limited to, liver tissue, skeletal muscle, heart, brain, and adipose tissue.Mitochondria can be isolated from cells of autogenous, allogeneic, and / or xenogeneic origin.In some cases, mitochondria are isolated from cells that have undergone genetic modification, for example, cells that have undergone mtDNA modification or nuclear DNA modification.
[0076] Mitochondria can be isolated from cells or tissues by any means known to those skilled in the art.In one example, tissue or cell samples are collected and then homogenized.Following homogenization, mitochondria are isolated by repeated centrifugation.Alternatively, cell homogenate can be filtered through nylon mesh filter. Exemplary methods for isolating mitochondria are described, for example, in McCully JD, Cowan DB, Pacak CA, Toumpoulis IK, Dayalan H and Levitsky S, "Injection of isolated mitochondria during early reperfusion for cardioprotection," Am J Physiol 296, H94-H105. PMC2637784 (2009); Frezza, C., Cipolat, S., & Scorrano, L, "Organelle isolation: functional mitochondria from mouse liver, muscle and cultured filroblasts." Nature Protocols, 2(2), 287-295 (2007); and the PCT application entitled "Products and Methods to Isolate Mitochondria" (PCT / US2015 / 035584; International Publication No. 2015192020); each of which is incorporated by reference.
[0077] Methods for Making Combined Mitochondrial Agents A skilled practitioner will recognize that an agent can be coupled to mitochondria in any number of ways, for example, by being attached to the mitochondria, fully or partially embedded in the mitochondrial membrane, encapsulated in the mitochondria, or enclosed within the mitochondria.
[0078] Without being bound by any theory or any particular approach, it is believed that the outer membrane of mitochondria is adhesive, and therefore is particularly suitable for combination with various active substances.In some embodiments, pharmaceutical substances can be attached to the outer membrane of mitochondria simply by incubation.For example, an effective amount of pharmaceutical substance can be thoroughly mixed with isolated mitochondria in a buffer solution, such as a respiratory buffer solution, at a temperature favorable to isolated mitochondria, for example, 0°C to 26°C, 0°C to 4°C, or about 0°C, 4°C, 26°C.This procedure is useful for attaching an effective amount of pharmaceutical substance (e.g., nanoparticles, DNA vectors, RNA vectors) to mitochondria.
[0079] In some embodiments, organic cations (e.g., rhodamine and tetramethylrosamine) are readily sequestered by functional mitochondria due to the potential on the mitochondrial membrane. Healthy mitochondrial membranes maintain a potential difference between the inside and outside of the organelle, called the membrane potential. This membrane potential is a direct result of mitochondrial functional processes and can be lost if mitochondria do not function properly. Lipid-soluble cations are taken up by mitochondria as a result of their positive charge and solubility in both the inner membrane lipids and the matrix aqueous space. Similarly, in some other embodiments, anions can attach to the outer mitochondrial membrane due to their negative charge. To allow mitochondria to bind these pharmaceutical substances, an effective amount of the pharmaceutical substance should be thoroughly mixed with isolated mitochondria in a buffer, such as a respiratory buffer, at a temperature favorable to the isolated mitochondria, such as about 0°C or 4°C.
[0080] Therapeutic, diagnostic, and / or imaging agents can be chemically linked to phospholipids, peptides, or proteins on the mitochondrial membrane. For example, molecules including fluorophores (pHrodo Red (Thermo Fisher Scientific, Inc.)) and metal particles (e.g., 30 nm magnetic iron oxide nanoparticles (Sigma)) can be covalently linked to exposed amine groups on proteins and peptides exposed on the outer membrane of intact mitochondria using succinimidyl ester conjugates. These reactive reagents react with unprotonated aliphatic amine groups, including the amine termini of proteins and the ε-amino groups of lysine residues, to create stable carboxamide bonds. In another example, when pharmaceutical agents, such as MitoTracker® Orange CMTMRos (Invitrogen, Carlsbad, CA, now Thermo-Fisher Scientific, Cambridge, MA), are mixed with functional mitochondria, they are oxidized and then react with thiols on proteins and peptides on the mitochondria to form conjugates.
[0081] There are numerous reactive chemical moieties available for attaching therapeutic, diagnostic, and / or imaging agents to the surface of mitochondria (e.g., functionalized carboxylic acids, amines, etc.).
[0082] The agent can be attached to either the outer or inner mitochondrial membrane via protein bonds, amine bonds, or other attachment methods. Alternatively, or additionally, the agent can be attached to the mitochondrial membrane via hydrophobic, van der Waals, and / or electrostatic interactions.
[0083] In many cases, therapeutic, diagnostic, and imaging agents may be simply mixed with isolated mitochondria and incubated in a buffer (e.g., a respiration buffer) for a sufficient time (e.g., several minutes, 5 minutes, 10 minutes, or 1 hour) under favorable conditions (e.g., 0°C to 26°C, 0°C to 4°C, or about 0°C, 4°C, 26°C, pH 7.2 to 8.0).
[0084] Exemplary methods for preparing combined mitochondrial agents are described in McCully et al., Injection of isolated mitochondria during early reperfusion for cardioprotection, Am J Physiol 296, H94-H105. PMC2637784 (2009); and Masuzawa et al., Transplantation of autologously derived mitochondria protects the heart from ischemia-reperfusion injury, Am J Physiol 304, H966-982. PMC3625892 (2013). Each of the foregoing is incorporated by reference in its entirety.
[0085] Methods for preparing compositions containing mitochondria and / or combined mitochondrial agents The isolated mitochondria and the combined mitochondrial agent can be mixed with a pharmaceutically acceptable carrier to form a pharmaceutical composition. Pharmaceutically acceptable carriers include any compound or composition (including but not limited to suitable vehicles, diluents, solvents, excipients, pH adjusters, salts, colorants, rheology adjusters, lubricants, coating agents, fillers, antifoaming agents, polymers, hydrogels, surfactants, emulsifiers, adjuvants, preservatives, phospholipids, fatty acids, mono-, di- and triglycerides and their derivatives, waxes, oils, and water) that are useful for promoting the preservation, stability, administration, cell targeting, and / or delivery of the mitochondria and / or the combined mitochondrial agent. In some embodiments, the isolated mitochondria and / or the combined mitochondrial agent are suspended in water, saline, buffer, respiratory buffer, or sterile mitochondrial buffer for in vivo delivery. Pharmaceutically acceptable salts, buffers, or buffer systems, including but not limited to saline, phosphate buffer, phosphate-buffered saline (PBS), or respiratory buffer, can be included in the compositions described herein. Vehicles capable of facilitating in vivo delivery to cells, such as liposomes, may be utilized to facilitate delivery of the combined mitochondrial agent to target cells.
[0086] Methods for making compositions, such as liquid, semi-solid, and solid compositions (e.g., solutions, creams, lotions, ointments, oils, among others), are well known in the art. A skilled practitioner will recognize that such known methods can be modified to add one or more steps to add mitochondria and / or combined mitochondrial agents to form the compositions described herein. A skilled practitioner will recognize that in some cases, the compositions described herein may contain more than one type of combined mitochondrial agent. For example, compositions containing mitochondria in which essentially each mitochondrion is associated with multiple types of agents are included. Also included are compositions containing mitochondria in which each mitochondrion is paired with only one type of agent, but the composition contains a mixture of mitochondrial / agent pairs.
[0087] Usage Administration The isolated mitochondria and combined mitochondrial agents can be administered to patients by injection intravenously, intraarterially, intraperitoneally, intramuscularly, and / or via intraosseous injection. In some embodiments, the isolated mitochondria and combined mitochondrial agents can be delivered by direct injection or by vascular infusion.
[0088] Once mitochondria are injected into tissue, they will be taken up by cells surrounding the injection site. Therefore, in some embodiments, the injection site is the target site. In some other embodiments, mitochondria are injected into blood vessels that carry blood to the target site, such as an organ, tissue, or injury site. Without being bound by any theory, evidence suggests that mitochondria delivered by direct injection are internalized by cells via actin-dependent endocytosis. However, the uptake of mitochondria via intravascular delivery appears to be more complex. The rapid and widespread uptake of mitochondria when delivered by vascular injection suggests that a mechanism is involved that allows mitochondria to rapidly pass through the blood vessel wall. Some studies support the notion that cells can routinely leak out of the blood circulation. It has been shown that certain cardiac and mesenchymal stem cells appear to actively exit the vasculature through a process distinct from extravasation (Cheng, K., Shen, D., Xie, Y., Cingolani, E., Malliaras, K., Marban, E., 2012, Brief report: Mechanism of extravasation of infused stem cells. Stem Cells. 30, 2835-2842.; Allen, TA, Gracieux, D., Talib, M., Tokarz, DA, Hensley, MT, Cores, J., Vandergriff, A., Tang, J., de Andrade, JB, Dinh, PU, Yoder, JA, Cheng, K., 2017. Angiopellosis as an Alternative Mechanism of Cell Extravasation. Stem Cells. 35,170-180). Migration of stem cells through the vessel wall requires extensive remodeling of the endothelium. Mitochondria may use a similar remodeling mechanism to cross the vessel wall. Another possible mechanism of mitochondrial uptake may be an extravasation-like mechanism.Some cells routinely leak out of the blood circulation. For example, leukocyte extravasation (i.e., transmigration) between venous endothelial cells is a well-understood process involving cell adhesion proteins. Furthermore, it is possible that injected mitochondria extravasate through the interendothelial space and through the capillary wall. After mitochondria cross the vascular endothelium, they are taken up by tissue cells via an actin-dependent internalization process in endosomes.
[0089] The mitochondria or combined mitochondrial agents can be administered to a subject as a single, one-time treatment, or alternatively, as multiple treatments, e.g., a course of treatment that continues intermittently or continuously for about 1, 2, 5, 8, 10, 20, 30, 50, or 60 days, a year, indefinitely, or until a physician determines that administration of the mitochondria or combined mitochondrial agents is no longer necessary.
[0090] In one administration method, mitochondria or a combination of mitochondrial agents are injected directly into the organ tissue. The injection is repeated several times at different sites in the organ. In such a method, a sterile 1 ml insulin syringe with a small needle (e.g., 28 gauge) can be used for injection, and each injection site can receive, for example, approximately 1.2 x 10 6 can receive mitochondria.
[0091] A skilled practitioner will recognize that the amount of mitochondria and / or combined mitochondrial agents, e.g., a composition containing mitochondria and / or combined mitochondrial agents, to be administered to a patient will vary depending, for example, on the type of disorder being treated, the route of administration, the duration of treatment, the size of the area to be treated, and / or the location of the treatment site on the patient, among other factors. A skilled practitioner will be able to determine the dosage to be administered depending on these and other variables. For example, a total of about 1×10 7can be administered to a subject's blood vessels to treat, for example, focal ischemia in the myocardium. As another example, for larger organs or affected areas, a larger number of mitochondria, e.g., 1 x 10 10 ~1×10 14 can be injected into the bloodstream. Conversely, for small focal lesions, 1 × 10 3 ~1×10 6 can be injected into a patient. Thus, an effective amount of mitochondria or a combined mitochondrial agent (or a composition comprising same) is the total amount of mitochondria or a combined mitochondrial agent sufficient to produce the desired therapeutic effect. An effective amount can be, for example, at least or about 1 x 10 2 mitochondria or combined mitochondrial agents, e.g., about 1 x 10 3 ~Approx. 1×10 14 , about 1×10 4 ~Approx. 1×10 13 , about 1×10 5 ~Approx. 1×10 12 , about 1×10 6 ~Approx. 1×10 11 , about 1×10 7 ~Approx. 1×10 10 , about 1×10 3 ~Approx. 1×10 7 , about 1×10 4 ~Approx. 1×10 6 , about 1×10 7 ~Approx. 1×10 14 , or approximately 1 × 10 8 ~Approx. 1×10 13 , about 1×10 9 ~Approx. 1×10 12 , about 1×10 5 ~Approx. 1×10 8 , or at least or about 1×10 3 , 1×10 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12, 1×10 13 , or at least or about 1×10 14 , or for example, 1 x 10 14 As used herein, the term "total amount" refers to the total amount of mitochondria or combined mitochondrial agents in the context of administration to a patient, in a single administration (e.g., a single injection, a single dose administered in an infusion) or multiple administrations (e.g., multiple injections), depending on the dosage regimen being implemented.
[0092] The isolated mitochondria and / or combined mitochondrial agents can be administered to a subject by various routes, e.g., direct injection, intravascular delivery, every 12 to 24 hours. In some embodiments, the isolated mitochondria or combined mitochondrial agents can be administered to a subject by various routes, e.g., direct injection, intravascular infusion, every 5 to 10 minutes (e.g., every 5 minutes, every 10 minutes).
[0093] In some embodiments, isolated mitochondria or combined mitochondrial agents can be injected directly into tissues or organs through 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, and 34 gauge needles. In some other cases, isolated mitochondria or combined mitochondrial agents can be delivered to the target site by catheter.
[0094] It should be noted that in some cases, the effect of mitochondria depends on the time between the time of isolation and the time of use.Therefore, in some cases, mitochondria are freshly isolated and viable.Mitochondria or a combination of mitochondrial agents can be administered to a subject within about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, or about 120 minutes after mitochondria are isolated.In some cases, mitochondria or a combination of mitochondrial agents can be administered to a subject within about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, or about 120 minutes after the start of the mitochondrial isolation process. The mitochondria and / or combined mitochondrial agents may, in some cases, be stored for a short period of time (e.g., about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, or about 60 minutes) before use.
[0095] It is also noted that in some cases, frozen-thawed mitochondria are not viable and are not effective in certain treatments described herein, such as the treatment of ischemia / reperfusion injury. Thus, in some cases, mitochondria are not frozen and thawed after isolation from tissues and / or cells.
[0096] The mitochondria for treatment can be isolated from cells or tissues of autologous, allogeneic and xenogeneic origin.In some cases, mitochondria are collected from the cultured cells or tissues of a subject, and these mitochondria are administered back to the same subject.In some other cases, mitochondria are collected from the cultured cells or tissues of a second subject, and these mitochondria are administered to the first subject.In some cases, mitochondria are collected from the cultured cells or tissues of different species (for example, mouse, pig, yeast) of different species.
[0097] Treatment of ischemic heart and other ischemia-related diseases The heart is a highly active organ that requires a continuous supply of oxygen to maintain normal function. Under aerobic conditions, the heart obtains its energy primarily from mitochondria, which account for 30% of the total volume of the cardiomyocyte. Following the onset of ischemia, there is a rapid decline in high-energy phosphate levels, accompanied by alterations in mitochondrial structure, volume, oxygen consumption, and ATP synthesis.
[0098] Attempts to reduce myocardial tissue necrosis and improve postischemic function using pharmacological and / or exogenous substance interventions, either alone or in combination with treatment techniques, have so far offered limited cardioprotection. Despite these interventions, mitochondrial damage and dysfunction continue to represent a major problem after myocardial ischemia and remain a significant cause of morbidity and mortality.
[0099] Mitochondrial damage occurs primarily during ischemia rather than during reperfusion, and preservation of mitochondrial respiratory function enhances contractile recovery and reduces myocardial infarct size.
[0100] The method described herein can be used to treat ischemic heart.For example, an effective amount of isolated mitochondria can be injected into the blood vessel of a subject, for example, into the coronary vasculature of a subject.For example, about 1 × 10 7 The mitochondria can be administered to the coronary vasculature of a subject. After transplantation, the injected mitochondria are internalized by cardiomyocytes, providing enhanced oxygen consumption, upregulating chemokines that enhance cardiac function after infarction, and upregulating the expression of protein pathways that are important in preserving myocardial energetics. In another example, an effective amount of mitochondria can be directly injected into the risk area (region of focal ischemia). The injection can be repeated several times at different sites in the heart.
[0101] Reperfusion injury is tissue damage caused by blood supply when blood returns to tissue after a period of ischemia or oxygen deprivation. The lack of oxygen and nutrients during the ischemic period leads to inflammation and oxidative damage when blood flow is restored. The inflammatory response further leads to tissue reperfusion injury. Therefore, in some cases, treatment also involves administering an immunosuppressant to the patient. The immunosuppressant can be administered, for example, separately but as a combined treatment with a mitochondrial agent. Alternatively, or additionally, the immunosuppressant can be linked to mitochondria to form a combined mitochondrial agent, which can be used for treatment. Particularly useful immunosuppressants are bisphosphonates.
[0102] Ischemia / reperfusion injury in several other organs is also often associated with mitochondrial damage and dysfunction. These organs include, but are not limited to, lungs, kidneys, liver, skeletal muscle, brain, etc. These injuries or diseases include, but are not limited to, ischemic colitis, mesenteric ischemia, cerebral ischemia, stroke, acute limb ischemia, cyanosis, and gangrene. The described methods can also be used to treat ischemic injury in these organs / tissues. For these treatments, isolated mitochondria and / or combined mitochondrial agents can be injected directly into the organ tissue or into the blood vessels that carry blood to the target organ / tissue or injury site of interest.
[0103] Vasodilation and blood flow It has been demonstrated that the delivery of mitochondria by intravascular injection significantly increases coronary blood flow without changing mean blood pressure or heart rate.The ability to increase blood flow without increasing heart rate allows clinical application in angina-type injury and ischemia / reperfusion-related injury, and in tissue damage areas where increased blood flow and oxygen delivery are required.Therefore, the method described herein can be used in coronary intervention to remove thrombus or obstruction in blood vessels.
[0104] The methods described herein can also be used to increase blood flow and / or oxygen delivery for various organs or tissues (e.g., heart, lungs, kidneys, brain, skeletal muscles). In some cases, the methods described herein can be used to treat peripheral vascular disease. Peripheral vascular disease (PVD) is a blood circulation disorder that causes narrowing, blockage, or spasm of blood vessels other than the heart and brain. This can occur in both arteries and veins. PVD typically causes pain and fatigue, often in the legs, especially during exercise. Isolated mitochondria and / or combined mitochondrial agents can be injected into blood vessels. The blood flow can carry the isolated mitochondria or combined mitochondrial agents to the target site. In some cases, the methods described herein can also be used to enhance smooth muscle function.
[0105] The methods described herein can also be used for vasodilation in various organs.In some cases, isolated mitochondria or combined mitochondrial agents can be used to reduce the vascular resistance of organs (e.g., heart, kidney, liver, or lung).Isolated mitochondria or combined mitochondrial agents can be used to increase blood flow for angiography.Isolated mitochondria and / or combined mitochondrial agents can be added to contrast agents and used to identify and remove blockages.
[0106] The methods described herein can be used to treat blocked blood vessels, for example, by locating a thrombus, placing a first catheter with a cage distal to the thrombus, placing a second catheter proximal to the thrombus, injecting mitochondria and / or a combined mitochondrial agent through the proximal catheter to cause vasodilation, collecting the thrombus in a basket, and removing the thrombus.
[0107] It should be noted that the effect of vascular injection of mitochondria depends on the time from isolation to use. The vasodilatory effect decreases as the time from isolation increases. Without being bound by any theory, it is hypothesized that freshly isolated mitochondria have certain chemicals that can increase blood flow. Therefore, in some methods, the mitochondria are freshly isolated and viable. For example, the mitochondria or the combined mitochondrial agent are administered to a subject within about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, or about 120 minutes from the start of the mitochondrial isolation process or after the mitochondria are isolated. In some cases, the mitochondria or the combined mitochondrial agent are administered to a subject within about 20 minutes to about 60 minutes (e.g., about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, or about 60 minutes) from the start of the mitochondrial isolation process or after the mitochondria are isolated.
[0108] In some cases, increasing blood flow is undesirable (e.g., when treating pulmonary ischemia / reperfusion). In these cases, the mitochondria or combined mitochondrial agents can be stored for a short period of time (e.g., about 30 to about 60 minutes) before use. This method can be used to increase tissue viability without increasing blood flow (e.g., when treating ischemia / reperfusion injury). In these cases, the mitochondria or combined mitochondrial agents are administered to the subject at least about 60 minutes (e.g., about 65 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, about 120 minutes) from the time the mitochondrial isolation process begins or after the mitochondria are isolated.
[0109] cardiac surgery The isolated mitochondria and / or the combined mitochondrial agent can be delivered to the heart to reduce stunning and allow the heart to recover from surgery (for example, cardiac arrest) and without increasing heart rate or heart oxygen demand.In some embodiments, the method involves the direct injection of the isolated mitochondria and / or the combined mitochondrial agent into the heart.In some methods, the isolated mitochondria and / or the combined mitochondrial agent is injected into coronary artery.
[0110] Imaging Imaging agents can be attached to mitochondria, often by co-incubation of the mitochondria with the imaging agent. Such imaging agents include MitoTracker and pHrodo fluorophores from Thermo Fisher Scientific Inc. 18 F-rhodamine 6G, and iron oxide nanoparticles.
[0111] The combined mitochondrial agent containing imaging material can be injected into tissue or perfused through blood vessels.The tissue containing labeled mitochondria can be examined using imaging techniques, such as positron emission tomography (PET), micro-computed tomography (μCT), and magnetic resonance imaging (MRI), bright-field microscopy, and 3D super-resolution microscopy.Skilled practitioners will recognize that other imaging techniques or modalities can also be used.These include, but are not limited to, X-ray, scintigraphy, fluorescence, and ultrasound.
[0112] Positron emission tomography is an imaging technique that produces a three-dimensional image of the body, and can be used in the methods described herein. The system detects gamma-ray pairs indirectly emitted by positron-emitting radioisotopes (tracers). Then, a three-dimensional image of the tracer concentration in the body is constructed by computer analysis. Useful reporter groups include: 11 C. 13 N, 15 O. 18 F, 64 Cu, 68 Ga, 81 mKr, 82 Rb, 86 Y, 89 Zr, 111 In, 123 I, 124 I, 133 Xe, 201 Tl, 125 I, 35 S 14 C. 3 In some methods, radioisotopes, e.g., 18 by F or molecules incorporating radioisotopes, e.g. 18 F-rhodamine 6G, 18 Mitochondria can be labeled with F-labeled rhodamine B. After the mitochondria are internalized by the target cells, PET imaging techniques, or similar techniques, can be employed to view the target cells.
[0113] Magnetic resonance imaging is a medical imaging technique that images the body's anatomy and physiological processes and can be used in the methods described herein. In some cases, it can be used in conjunction with other imaging techniques, such as PET. Images from both devices can be taken consecutively in the same session and combined into a single superimposed (co-registered) image. PET / MRI scans can be used to diagnose health conditions in humans and animals, for example, for research, medical, and agricultural purposes.
[0114] Micro-computed tomography uses X-rays to generate cross-sections of physical objects, which can be used to recreate virtual models without destroying the original object and can be used in the methods described herein. In some cases, it is used in conjunction with other imaging techniques, such as PET. Images acquired from both devices can be taken consecutively in the same session and combined into a single superimposed (co-registered) image. Thus, functional images obtained by PET, which depict the spatial distribution of metabolic or biochemical activity in the body, can be more accurately aligned or correlated with anatomical images obtained by CT scanning. Two-dimensional and three-dimensional image reconstructions can be rendered according to common software and control systems.
[0115] 3D structured illumination microscopy, 3D-SIM, or 3D super-resolution microscopy, allows for the complete 3D visualization of the internal structure of cells and can be used in the methods described herein. Structured illumination microscopy is an imaging method that can double the spatial resolution of conventional wide-field fluorescence microscopes by using spatially structured illumination light. It enhances spatial resolution by collecting information from frequency space outside the observable region.
[0116] The described methods, i.e., methods comprising administering mitochondria and / or combined mitochondrial agents, are useful for diagnosing various diseases, such as cancer (e.g., lung cancer, brain cancer, pancreatic cancer, melanoma, prostate cancer, colon cancer), cardiovascular disease (e.g., myocardial infarction, atherosclerosis), autoimmune diseases (e.g., multiple sclerosis, diabetes, irritable bowel syndrome, celiac disease, Crohn's disease), and inflammatory diseases.
[0117] Methods of using agents for imaging purposes are well known in the art, see, for example, Bartholoma MD, He H, Pacak CA, Dunning P, Fahey FH, McGowan FX, Cowan DB, Treves ST and Packard AB, Biological characterization of F18-labeled rhodamine B, a potential positron emission tomography perfusion tracer, Nucl Med Biol 40, 1043-1048, PMC3820364(2013); Bartholoma MD, Zhang S, Akurathi V, Pacak CA, Dunning P, Fahey FH, Cowan DB, Treves ST and Packard AB, 18 F-labeled rhodamines as potential myocardial perfusion agents: comparison of pharmacokinetic properties of several rhodamines, Nucl Med Biol 42, 796-803, PMC4567415(2015); and Pacak CA, Hammer PE, MacKay AA, Dowd RP, Wang KR, Masuzawa A, Sill B, McCully JD and Cowan DB, Superparamagnetic iron oxide nanoparticles function as a long-term, multi-modal imaging label for non-invasive tracking of implanted progenitor cells, PLoS ONE 9, e108695, PMC4177390(2014). Each of the foregoing can be useful in the methods described herein and is incorporated by reference in its entirety.
[0118] Drug delivery The present disclosure provides a method for delivering pharmaceutical substances to, for example, cells and / or tissues of a patient. Mitochondria are taken up into tissue cells via an actin-dependent internalization process, thereby providing a method for directly delivering pharmaceutical substances to cells. Furthermore, since the combined mitochondrial agent is more likely to cross the endothelium of blood vessels near the injection site, in some cases, the combined mitochondrial agent can be injected into blood vessels carrying blood to the target site. In some cases, the combined mitochondrial agent enters tissues through the endothelium of capillaries.
[0119] The antibody or antigen-binding fragment can be linked or attached to the mitochondria. A skilled practitioner will recognize that linking the antibody or antigen-binding fragment to the mitochondria or the combined mitochondrial agent can enable the mitochondria or the combined mitochondrial agent to be targeted to a specific site, e.g., a target cell and / or tissue. In some cases, the antibody or antigen-binding fragment is designed to target a specific cell type, e.g., pulmonary smooth muscle cells, immune cells, macrophages, etc.
[0120] gene therapy Gene therapy is the therapeutic delivery of nucleic acid polymers to a patient's cells as drugs to treat diseases. Isolated mitochondria can be used as a carrier to deliver nucleic acid polymers to cells. In some cases, a combined mitochondrial agent containing a nucleic acid polymer can be administered to a subject to replace a disease-causing mutant gene, inactivate (i.e., "knock out") the mutant gene, or introduce a new gene into the subject. Exemplary nucleic acid polymers include, but are not limited to, double-stranded DNA, single-stranded DNA, double-stranded RNA, single-stranded RNA, or triple-helical nucleic acid molecules. In certain cases, the nucleic acid polymer is DNA, interfering RNA (siRNA), and microRNA. In the case of mitochondrial myopathy associated with mitochondrial DNA dysfunction, gene therapy can be performed by direct injection of mitochondria into skeletal muscle or muscle. In the case of mitochondrial myopathy associated with nuclear DNA, multiple injections over time may be beneficial or required.
[0121] Minimizing Cardiotoxicity Chemotherapy is a common treatment for various cancers, but it also causes several serious complications. Chemotherapy-induced cardiotoxicity is one complication that limits the clinical use of chemotherapy agents. Certain chemotherapy agents, such as anthracyclines, are highly effective against acute lymphoblastic and myeloblastic leukemia, but are particularly harmful to the heart due to their effects on mitochondria. Damage to mitochondria further leads to chemotherapy-induced cardiotoxicity. Angsutararux P, Luanpitpong S, Issaragrisil S. Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress. Oxid Med Cell Longev. 2015; 2015: 795602. doi: 10.1155 / 2015 / 795602(2015); Guo S, Wong S. Cardiovascularities toxic from systemic breast cancer therapy, Front Oncol. 4:346. doi: 10.3389 / fonc.2014.00346. eCollection(2014).
[0122] One useful method for minimizing chemotherapy-induced cardiac toxicity is to administer an effective amount of isolated mitochondria and / or combined mitochondrial agents to patients currently undergoing chemotherapy treatment regimen.If patient needs to be treated with chemotherapy (for example, because prescribed by a doctor or veterinarian), patient can be treated with mitochondria and / or combined mitochondrial agents before, during, and / or after the administration of chemotherapy.For example, patient can be treated with mitochondria and / or combined mitochondrial agents immediately after administration, as the only treatment, or intermittently or continuously for about 1, 2, 5, 8, 10, 20, 30, 50, or 60 days, 1 year, indefinitely, or until a doctor determines that the administration of mitochondria and / or combined mitochondrial agents is no longer necessary.
[0123] Organ / Tissue Transplantation The present disclosure also features a method for transplanting organs, tissues, cell masses, and / or isolated cells. The method can include exposing the organs, tissues, cell masses, and / or isolated cells to mitochondria or a combination of mitochondrial agents before transplantation. Such exposure can be performed in situ and / or ex vivo. The organs, tissues, and / or isolated cells can be exposed to a composition containing mitochondria or a combination of mitochondrial agents.
[0124] The exposure of organs or tissues to compositions comprising mitochondria or combined mitochondrial agents can be carried out ex vivo and / or in situ by any method known in the art.For example, the exposure can be carried out ex vivo in any chamber or space with a volume sufficient to completely or partially immerse the organ or tissue in the composition.As another example, the organ can be exposed to compositions comprising mitochondria or combined mitochondrial agents by placing the organ in any suitable container and allowing the composition to "wash over" the organ so that the organ is exposed to a continuous flow of the composition comprising mitochondria or combined mitochondrial agents.
[0125] Alternatively, the organ may be perfused with a composition containing mitochondria or a combination of mitochondrial agents. The term "perfusion" is an art-recognized term and refers to the passage of a fluid, e.g., a composition containing mitochondria or a combination of mitochondrial agents, through the blood vessels of an organ or tissue. Methods for perfusing organs ex vivo and in situ are well known in the art. Organs can be perfused ex vivo with a composition, e.g., by continuous cryostat perfusion (see, Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994). Optionally, for in situ or ex vivo perfusion, before perfusion with a composition containing mitochondria or a combination of mitochondrial agents, the organ can be perfused with a washing solution, e.g., UW solution, to remove donor blood from the organ. Alternatively, UW solution can contain mitochondria or a combination of mitochondrial agents.
[0126] Organ or tissue can be placed in, for example, immersed in, a medium or solution containing mitochondria or a combination of mitochondrial agents.Alternatively, or in addition, mitochondria or a combination of mitochondrial agents can be added to the medium or solution.In situ exposure can be carried out by any method known in the art, for example, by in situ flushing or perfusion of the organ with a composition containing mitochondria or a combination of mitochondrial agents (see Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994).
[0127] The present disclosure contemplates that any or all of the above methods for exposing, e.g., washing, immersing, or perfusing, an organ or tissue with a composition comprising mitochondria or combined mitochondrial agents can be used in a given transplant procedure.
[0128] The present disclosure further contemplates that it can create solid or semi-solid compositions.For example, the liquid that comprises the above-mentioned mitochondria or the combined mitochondrial agent composition can be made into the solid or semi-solid composition that organ or tissue can be layered or embedded in.Alternatively, semi-solid composition can be injected into organ.For example, solid or semi-solid compositions can be made by adding a solidifying agent such as gelling agent (for example, collagen or alginate) to the liquid.
[0129] The methods described herein can be used to control ischemia / reperfusion injury for transplanted organs. Ischemia-reperfusion injury is a very important problem during organ transplantation. Major damage in organ transplants appears to be induced by reperfusion injury. Organs used for transplantation often undergo prolonged cold ischemic storage after devascularization and cold perfusion, resulting in increased susceptibility to injury during reperfusion. Evidence indicates that ischemia / reperfusion injury often leads to mitochondrial oxidative damage, which can cause delayed graft function. Dare AJ, Logan A, Prime TA, Rogatti S, Goddard M, Bolton EM, Bradley JA, Pettigrew GJ, Murphy MP, Saeb-Parsy K. The mitochondria-targeted anti-oxidant MitoQ decreases ischemia-reperfusion injury in a murine syngeneic heart transplant model, J Heart Lung Transplant, 34(11):1471-80. doi: 10.1016 / j.healun.2015.05.007(2015); Liu Q, Krishnasamy Y, Rehman H, Lemasters JJ, Schnellmann RG, Zhong Z. Disrupted Renal Mitochondrial Homeostasis after Liver Transplantation in Rats. PLoS One 10(10): e0140906. doi: 10.1371 / journal.pone.0140906(2015). In some cases, the transplant organ can be, for example, a heart, lung, kidney, or liver. In one embodiment, an effective amount (e.g., 1×10 7 , 1×10 8 ) mitochondria or a combined mitochondrial agent is injected into the blood vessels (e.g., arteries) of the transplant organ. In another embodiment, an effective amount (e.g., 1 x 10 7 , 1×10 8) mitochondria or a combination of mitochondrial agents are injected directly into organ tissue.
[0130] An effective amount of mitochondria or a combination of mitochondrial agents is an amount effective for enhancing the survival and / or improving the function of organs or cells in vivo and / or in vitro.In the context of transplantation of individual cells or cell masses, for example, transplant donors and / or recipients, an effective amount of mitochondria or a combination of mitochondrial agents is the amount administered to transplant donors and / or recipients that is sufficient to enhance the survival of cells or cell masses, for example, to reduce the loss of cells or cell masses, and / or improve the functional performance of transplanted cells or cell masses.In the context of treating ex vivo cells, for example, pancreatic islet cells, that are cultured and / or used for transplantation, an effective amount is the amount that cells are incubated or preserved in order to enhance cell preservation and / or reduce cell loss, for example, loss through apoptosis, and / or enhance function. Within the context of organ and tissue transplantation, e.g., transplant donors and / or recipients, an effective amount of mitochondria or combined mitochondrial agents is the amount administered to the transplant donor and / or recipient sufficient to enhance survival of the organ, tissue, or cells of interest, e.g., reduce loss of cells from which the organ or tissue is composed, and / or improve the functional performance of the organ.
[0131] In some cases, the injection is performed before the organ is retrieved from the donor. In some cases, the injection is performed at some time after the organ is retrieved but before transplantation. In some cases, the injection is performed after the organ is transplanted into a recipient. In some cases, the injection is performed before organ retrieval, after organ harvesting, and then after transplantation back into a recipient. In some cases, the injection is performed during transplant surgery. In some embodiments, the transplant organ is preserved in a solution containing an effective amount of isolated mitochondria or a combined mitochondrial agent. In some cases, the solution is University of Wisconsin cold preservation solution.
[0132] A major limitation of organ transplantation is the availability of donor organs. To increase the number of donor organs, centers may use organs from extended-criteria donors or donors who have died cardiac death. In these cases, the described method can improve organ quality and therefore increase donor organ availability.
[0133] The present disclosure also provides a method for improving the integration of transplanted tissue and / or cells. In some embodiments, the tissue is skin tissue or bone marrow. In some embodiments, the cell is a stem cell. In these cases, mitochondria or a combined mitochondrial agent can improve the integration of transplanted tissue and cells in the recipient's body.
[0134] Treatment of mitochondrial dysfunction disorders Due to the key function of mitochondria in cellular metabolism, mitochondrial damage and dysfunction can lead to a variety of human diseases. Diseases caused by mutations in mtDNA include Kearns-Sayre syndrome, MELAS syndrome, Leber hereditary optic neuropathy, Pierson syndrome, and progressive external ophthalmoplegia. Other diseases associated with mitochondrial dysfunction include, but are not limited to, mitochondrial myopathy, diabetes mellitus and deafness (DAD), Leigh syndrome, "neuropathy, ataxia, retinitis pigmentosa, and ptosis" (NARP), myoneurogenic gastrointestinal encephalopathy (MNGIE), myoclonic epilepsy with ragged red fibers (MERRF syndrome), encephalomyopathies, lactic acidosis, Parkinson's disease, and stroke-like symptoms (MELAS syndrome).
[0135] Furthermore, mitochondrial damage and dysfunction can also be caused by injury, toxicity, chemotherapy, and age-related changes. Mitochondrial dysfunction can further interfere with the proper functioning of a subject's tissue or organ.
[0136] This disclosure demonstrates that mitochondrial transplantation has the potential to rescue cellular function and replace damaged or dysfunctional mitochondria. Because mitochondria can be effectively delivered to tissues via vascular injection, the methods described herein relate to novel methods for treating mitochondrial dysfunction disorders.
[0137] The mitochondria for treatment can be isolated from cells of autologous, allogeneic and xenogeneic origin.The purpose is to administer fully functional mitochondria to the subject to achieve desired therapeutic effect.In one embodiment, isolated mitochondria or combined mitochondrial agents are administered to the patient in an amount sufficient to treat mitochondrial dysfunction.Because the symptoms of mitochondrial dysfunction are likely to appear in organs that require continuous energy supply, this administration can specifically target these affected organs, such as heart, brain and liver.In one embodiment, the injection site is the blood vessel that carries blood to the target organ.In another embodiment, this treatment involves systemic administration.
[0138] The methods described herein provide approaches to treating diabetes mellitus. Some forms of diabetes are caused by mitochondrial dysfunction in beta cells. At the pancreatic islet beta cell level, mitochondrial ATP production regulates acute insulin release, and mitochondrial ROS may contribute to the long-term decline in insulin secretory capacity seen in type 2 diabetes. Mitochondrial function also appears to be an important determinant of insulin sensitivity in muscle, liver, and adipose tissue. Sivitz, William I., and Mark A. Yorek. "Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities." Antioxidants & redox signaling 12.4(2010): 537-577. Treating these patients with isolated mitochondria or a combination of mitochondrial agents can restore normal beta cell function, thereby improving insulin production. In some embodiments, the method involves administering to the patient an effective amount of a composition containing isolated mitochondria or a combination of mitochondrial agents. The composition can be administered to patients by various routes, for example, the composition can be directly injected into pancreatic tissue, or the composition can be injected into the blood vessel that carries blood to the pancreas.In some cases, the blood vessel is the artery of the pancreas, for example, the large pancreatic artery.In some embodiments, pancreatic islet β cells are treated with isolated mitochondria or a combination of mitochondrial agents, and then transferred to a subject.These pancreatic islet β cells can be derived from the same subject or from different subjects.
[0139] In addition, the method described herein provides a way to treat Parkinson's disease. Parkinson's disease results from the dysfunction or death of dopamine-producing cells in the substantia nigra. The causes of cell dysfunction or cell death are poorly understood. Evidence suggests that reduced mitochondrial activity or mitochondrial dysfunction may be part of the cause. Therefore, administering an effective amount of isolated mitochondria or a combination of mitochondrial agents to Parkinson's disease patients can restore the normal function of dopamine-producing cells in these patients, thereby improving dopamine production.
[0140] Furthermore, mitochondrial dysfunction has been increasingly recognized as an important component of stress-related psychiatric disorders (e.g., post-traumatic stress disorder (PTSD)). The relationship between stress-related psychiatric disorders and mitochondrial dysfunction is described, for example, in Flaquer, A., et al. "Mitochondrial genetic variants identified to be associated with posttraumatic stress disorder." Translational psychiatry 5.3(2015): e524. Thus, in some cases, stress-related psychiatric disorders are also mitochondrial dysfunction disorders. Therefore, the methods described herein can also be used to treat stress-related psychiatric disorders, such as PTSD.
[0141] Injury treatment Injuries are often associated with mitochondrial damage and dysfunction. In some embodiments, the methods described herein can be used to treat a variety of injuries, such as traumatic brain injury, concussion, amputation injury, and the like.
[0142] Isolated mitochondria or combined mitochondrial agents can be used to treat wounds (for example, open wounds, burns, and rashes).Open wounds are injuries that involve the external or internal destruction of body tissues (for example, skin, muscle tissue, bone).In some cases, isolated mitochondria or combined mitochondrial agents can be directly injected into the tissues located around the wound.Alternatively, isolated mitochondria or combined mitochondrial agents can be applied locally to the wound site.In some embodiments, isolated mitochondria or combined mitochondrial agents can be administered to the subject by continuous infusion or by direct application to the injury site periodically, for example, every 2 hours, until the wound heals.
[0143] Cancer Treatment The methods described herein also provide cancer treatment. Cancer and tumor cells require a specialized blood supply that provides oxygen and other essential nutrients to grow beyond a certain size. They often induce blood vessel growth (angiogenesis) by secreting various growth factors (e.g., VEGF). Unlike normal blood vessels, tumor blood vessels are abnormally shaped, dilated, and have a more delicate vasculature. The extensive structure of tumor blood vessels provides a natural target site for drug delivery, as mitochondria containing therapeutic agents cross the vascular endothelium. After combined mitochondrial agents are injected into blood vessels, they are more likely to be delivered to tumor tissue than normal tissue. In one embodiment, cytostatic or cytotoxic agents can be delivered to tumors to kill cancer cells. In one embodiment, the therapeutic agent is a chemotherapeutic agent, such as an anthracycline. In a particularly useful embodiment, the described methods are used to treat pediatric neuroblastoma and prostate cancer.
[0144] The term "cancer" refers to cells capable of autonomous growth. Examples of such cells include cells with an abnormal state or pathology characterized by rapidly proliferating cell growth. The term is intended to include cancerous growths, such as tumors; oncogenic processes, metastatic tissues, and malignantly transformed cells, tissues, or organs (regardless of histopathological type or invasive stage). It also includes malignant tumors of various organ systems, such as the respiratory, cardiovascular, renal, reproductive, hematological, nervous, hepatic, digestive, and endocrine systems; and adenocarcinomas, including most malignant tumors, such as colon cancer, renal cell carcinoma, prostate cancer, and / or testicular cancer, non-small cell lung cancer, small intestine cancer, and esophageal cancer. "Naturally occurring" cancers include any cancers that are not experimentally induced by implantation of cancer cells into a subject, and include, for example, naturally occurring cancers, cancers caused by exposure of a patient to a carcinogen, cancers resulting from the insertion of transgenic oncogenes or knockout of tumor suppressor genes, and cancers caused by infection, such as viral infection. The term "carcinoma" is recognized in the art and refers to a malignant tumor of epithelial or endocrine tissue. The term also includes carcinosarcomas, which include malignant tumors composed of carcinomatous and sarcomatous tissue. "Adenocarcinoma" refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures. The term "sarcoma" is recognized in the art and refers to a malignant tumor of mesenchymal origin. The term "hematopoietic neoplastic disorder" includes diseases involving hyperplastic / neoplastic cells of hematopoietic origin. Hematopoietic neoplastic disorders can arise from the myeloid, lymphoid, or erythroid lineages, or their progenitor cells.
[0145] Cancers that may be treated using the methods and compositions of the present disclosure include, for example, cancer of the stomach, colon, rectum, oral cavity / pharynx, esophagus, larynx, liver, pancreas, lung, breast, cervix, uterine corpus, ovary, prostate, testicle, bladder, skin, bone, kidney, head, neck, and throat, Hodgkin's disease, non-Hodgkin's leukemia, sarcoma, choriocarcinoma, lymphoma, brain / central nervous system cancer, and neuroblastoma (e.g., childhood neuroblastoma), among others.
[0146] Furthermore, in some embodiments, the antibody or antigen-binding fragment can be linked or attached to mitochondria. A skilled practitioner will recognize that by linking the antibody or antigen-binding fragment to mitochondria or the combined mitochondrial agent, the mitochondria or the combined mitochondrial agent can be targeted to a specific site, for example, to a target cell and / or tissue. In some cases, the antibody or antigen-binding fragment is designed to target a specific cell type, for example, a cancer cell.
[0147] Treatment of metabolic disorders White adipose tissue, or white fat, is one of the two types of adipose tissue found in mammals. It is often used by the body as an energy store and contains many white adipocytes. The other type of adipose tissue is brown adipose tissue. The function of brown adipose tissue is to transfer energy from food to heat.
[0148] White adipocytes often contain a single lipid droplet.In contrast, brown adipocytes contain many smaller droplets and a large number of mitochondria.Understanding that human adulthood has a large energy-consuming organ in brown adipose tissue, targeting the thermogenesis of brown adipose tissue is currently considered to be a method for treating or preventing metabolic disorders such as obesity and its related metabolic diseases (e.g., type II diabetes).The use of brown adipose tissue for treating obesity and diabetes is described, for example, in Cypess, Aaron M., and C. Ronald Kahn. "Brown fat as a therapy for obesity and diabetes." Current opinion in endocrinology, diabetes, and obesity 17.2 (2010): 143, which is incorporated by reference in its entirety.
[0149] Since one main difference between brown adipocytes and white adipocytes is the number of mitochondria in cells, the present disclosure provides a method for treating and preventing metabolic disorders.These metabolic disorders include, but are not limited to, obesity and its related metabolic diseases (for example, type II diabetes).In some embodiments, isolated mitochondria and / or combined mitochondrial agents can be directly injected into the white adipose tissue of a subject.In some embodiments, the method involves identifying a subject with or at risk of metabolic disorders, and delivering mitochondria or combined mitochondrial agents to white adipose tissue by various routes (for example, direct injection, or injecting mitochondria or combined mitochondrial agents into the blood vessel that carries blood to white adipose tissue).In some embodiments, the method described herein can convert white adipose cells into brown adipocytes, and thus convert white adipose tissue into brown adipose tissue.
[0150] The isolated mitochondria and / or the combined mitochondrial agent can be administered to the subject by localized delivery.In some embodiments, this method involves determining the location of target site (for example, submental adipose tissue and abdominal adipose tissue), and injecting the composition comprising the isolated mitochondria and / or the combined mitochondrial agent into target site.In some cases, a small amount of this composition is delivered per injection, and the injection is repeated several times until the amount is sufficient to achieve the desired effect.
[0151] Cosmetic use Aged or damaged skin and muscle (for example, facial muscle) are associated with mitochondrial damage and dysfunction.Isolated mitochondria or combined mitochondrial agents can be used to improve the mitochondrial function of these damaged or aged tissues, thereby removing skin wrinkles, scars, or treating loose skin, burns, wounds, lipomas, etc.
[0152] In some embodiments, the method involves administering isolated mitochondria or combined mitochondrial agents to aged or damaged tissue (for example, skin tissue or facial muscle).In some cases, administration is carried out by 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, and 34 gauge hypodermic needle.In some other cases, isolated mitochondria or combined mitochondrial agents can be administered to aged or damaged tissue by local administration.Alternatively, a body part (for example, hand, foot) having aged or damaged tissue can be placed, for example, immersed, in a container (for example, a bathtub) filled with a medium or solution containing mitochondria or combined mitochondrial agents.In addition, mitochondria and / or combined mitochondrial agents can be administered to aged or damaged tissue by a continuous flow of the composition, for example, by pouring the composition into the tissue.
[0153] The composition may also contain an abrasive, which can effectively remove aged or damaged cells / tissues (e.g., aged skin tissue, dead cells on a wound) and expose relatively healthy cells or tissues underneath.The isolated mitochondria and / or the combined mitochondrial agent in the composition can then be incorporated into these relatively healthy cells or tissues, thereby improving the mitochondrial function of these cells or tissues.
[0154] The present disclosure also contemplates that liquid, paste, cream, gel, solid, and semi-solid compositions can be created. These compositions contain a mitochondrial agent or a combination of mitochondrial agents and are suitable for external use. For example, they can be used for topical treatment. Alternatively, they can be sprayed onto the skin or wound.
[0155] in vitro fertilization Mitochondrial genes are not inherited by the same mechanism as nuclear genes. They are typically inherited from only one parent. In humans, mitochondria originate from the egg, and therefore the mother. Mitochondrial donation is a specialized form of in vitro fertilization that prevents the mother's mutated mitochondrial genes from being passed on to the newborn. Typically, the future newborn's mitochondrial DNA comes from the egg of a third party. One notable problem with such a procedure is that it results in human offspring with three genetic parents, which has caused considerable controversy in the field of bioethics.
[0156] The described method provides a solution to this problem. In one embodiment, the cells of the future father are collected and cultured. Mitochondria are then isolated from the cultured cells. These mitochondria are then co-cultured with mitochondria-depleted eggs prepared for in vitro fertilization. In another embodiment, the father's mitochondria are co-cultured with the eggs, and in some cases, with the embryos. In these cases, even if the mother's mutated mitochondria have not been removed, the newborn can be treated for mitochondrial disease as long as there are sufficient functional and viable mitochondria in the eggs or embryos.
[0157] cell culture The present disclosure provides methods for maintaining or culturing animal cells in vitro. The animal cells can be cultured or simply maintained in the presence of a mitochondrial agent or a combination of mitochondrial agents.
[0158] A skilled practitioner will recognize that culture conditions, e.g., temperature, can be selected and / or modified depending on the cell type to be cultured (see, e.g., Cells: A Laboratory Manual, Spector and Leinwand, Eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1997). For example, the murine insulinoma cell line βTC3 (DSMZ, Braunschweig, Germany) can be incubated at 37°C in a humidified 5% CO2 / 95% air atmosphere.
[0159] Animal cells may be placed, for example, suspended or submerged, in a liquid medium. The medium may be any medium known to those skilled in the art that is suitable for culturing, storing, or washing the cells of interest (see, for example, Cells: A Laboratory Manual, Spector and Leinwand, Eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1997). Such types of medium include, but are not limited to, various buffers, Eagle's minimum essential medium (MEM), Dulbecco / Voigt's modified Eagle's minimum essential medium (DMEM), or Roswell Park Memorial Institute (RPMI) medium. Such media may also contain appropriate nutritional supplements, such as fetal bovine serum (FBS), individual amino acids, antibiotics, and / or vitamins. For example, the medium can be RPMI medium 1640 (Life Technologies, Grand Island, NY) supplemented with 2 mM L-glutamine, 100 U / ml penicillin G, 100 U / ml streptomycin, and 10% fetal calf serum (FCS) (Life Technologies). In embodiments in which the cells are in liquid medium, the cells can be exposed to a composition comprising mitochondria and / or combined mitochondrial agents.
[0160] The present disclosure also contemplates compositions comprising cells containing combined mitochondrial agents, allogeneic, xenogeneic, or autogenous mitochondria with appropriate genetic modifications. These cells can be any cells known in the art for various clinical uses, e.g., stem cells, or replacement cells. [Example]
[0161] The present invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
[0162] Example 1: Isolation of mitochondria from tissue samples or cultured cells Experiments were performed to isolate mitochondria from tissue samples or cultured cells.
[0163] preparation The following solutions were prepared for the isolation of intact, viable, and respiration-competent mitochondria. To successfully isolate mitochondria using this method, solutions and tissue samples should be kept on ice to preserve mitochondrial viability. Even when kept on ice, isolated mitochondria will exhibit a decrease in functional activity over time (Olson et al., J Biol Chem 242:325-332, 1967). These solutions should be prepared in advance, if possible. 1M K-HEPES stock solution (adjusted to pH 7.2 with KOH) 0.5M K-EGTA stock solution (adjusted to pH 8.0 with KOH) 1M KH2PO4 stock solution 1M MgCl2 stock solution Homogenization buffer (pH 7.2): 300 mM sucrose, 10 mM K-HEPES, and 1 mM K-EGTA. Stored at 4°C. Respiration buffer: 250 mM sucrose, 2 mM KH2PO4, 10 mM MgCl2, 20 mM K-HEPES buffer (pH 7.2), and 0.5 mM K-EGTA (pH 8.0). Stored at 4°C. 10x PBS stock solution: 80 g NaCl, 2 g KCl, 14.4 g NaHPO, and 2.4 g KHPO were dissolved in 1 L double-distilled H0 (pH 7.4). 1x PBS was prepared by pipetting 100 mL of 10x PBS into 1 L of double distilled H2O. Subtilisin A stock was prepared by weighing 4 mg of subtilisin A into a 1.5 mL microcentrifuge tube and stored at -20°C until use. BSA stock was prepared by weighing 20 mg of BSA into a 1.5 mL microcentrifuge tube and storing at -20°C until use.
[0164] Isolation of mitochondria from tissues A diagram outlining the procedural steps for mitochondrial isolation using tissue dissociation and differential filtration is shown in Figure 1. Two 6 mm biopsy sample punches were transferred to 5 mL of homogenization buffer in a dissociation C tube, and the sample was homogenized using the 1-minute homogenization program on the tissue dissociator (A). Subtilisin A stock solution (250 μL) was added to the homogenate in the dissociation C tube and incubated on ice for 10 minutes (B). The homogenate was centrifuged at 750 × G for 4 minutes (an optional step). The homogenate was filtered through a pre-wetted 40 μm mesh filter into a 50 mL conical centrifuge tube on ice, and then 250 μL of BSA stock solution was added to the filtrate (C). The filtrate was filtered again through a new pre-wetted 40 μm mesh filter into a 50 mL conical centrifuge tube on ice (D). The filtrate was filtered again through a new, pre-wetted 10 μm mesh filter into a 50 mL conical centrifuge tube on ice (E). The filtrate was filtered again through a new, pre-wetted 6 μm mesh filter into a 50 mL conical centrifuge tube on ice. The resulting filtrate could be used immediately or concentrated by centrifugation. For concentration, the filtrate was transferred to a 1.5 mL microcentrifuge tube and centrifuged at 9000 × g for 10 minutes at 4 °C (F). The supernatant was removed, and the pellet containing mitochondria was resuspended in 1 mL of respiration buffer and combined (G).
[0165] Immediately prior to isolation, subtilisin A was dissolved in 1 mL of homogenization buffer. Immediately prior to isolation, BSA was dissolved in 1 mL of homogenization buffer. Two fresh tissue samples were collected using a 6 mm biopsy punch and stored in 1x PBS in a 50 mL conical centrifuge tube on ice. The two 6 mm tissue punches were transferred to a Dissociation C Tube containing 5 mL of ice-cold Homogenization Buffer. The tissue was homogenized by placing the Dissociation C Tube on the tissue dissociator and selecting the preset mitochondrial isolation cycle (60 seconds of homogenization).
[0166] The Dissociation C tube was transferred to an ice bucket. Subtilisin A stock solution (250 μL) was added to the homogenate, mixed by inversion, and the homogenate was incubated on ice for 10 minutes. A 40 μm mesh filter was placed on a 50 mL conical centrifuge tube on ice, the filter was pre-wetted with homogenization buffer, and the homogenate was filtered into the 50 mL conical centrifuge tube on ice.
[0167] Freshly prepared BSA stock solution (250 μL) was added to the filtrate and mixed by inversion (this step was omitted if mitochondrial protein determination was required). A 40 μm mesh filter was placed on a 50 mL conical centrifuge tube on ice, the filter was pre-wetted with homogenization buffer, and the homogenate was filtered into the 50 mL conical centrifuge tube on ice. A 10 μm filter was placed on a 50 mL conical centrifuge tube on ice, the filter was pre-wetted with homogenization buffer, and the homogenate was filtered into the 50 mL conical centrifuge tube on ice. The filtrate was transferred to two pre-chilled 1.5 mL microcentrifuge tubes and centrifuged at 9000 × g for 10 min at 4 °C. The supernatant was removed, and the pellets were resuspended in 1 mL of ice-cold respiration buffer and combined.
[0168] Mitochondria isolated from tissue should be used immediately for injection or to prepare combined mitochondrial agents.
[0169] Isolation of mitochondria from cultured cells Mitochondria were also isolated from cultured cells using procedures essentially identical to those used to isolate mitochondria from tissue samples, except that human fibroblasts were used instead of biopsies.
[0170] Mitochondrial number The number of viable mitochondria was determined by labeling an aliquot (10 μl) of isolated mitochondria with MitoTracker Orange CMTMRos (5 μmol / L; Invitrogen, Carlsbad, CA, now Thermo-Fisher Scientific, Cambridge, MA). An aliquot of labeled mitochondria was spotted onto a slide and counted using a spinning disk confocal microscope equipped with a 63× C-apochromat objective (1.2 W Korr / 0.17 NA, Zeiss). Mitochondria were counterstained with the mitochondrial-specific dye MitoFluor Green (Invitrogen, Carlsbad, CA, now Thermo-Fisher Scientific, Cambridge, MA). Appropriate wavelengths were selected for measuring autofluorescence and background fluorescence using unstained cells and tissue. Briefly, 1 μl of labeled mitochondria was placed on a microscope slide and covered. The number of mitochondria was determined using MetaMorph imaging analysis software at low (×10) magnification, covering the entire specimen area.
[0171] Example 2: Preparation of combined mitochondrial agents Mitochondria 18 Experiments were performed combining F-rhodamine 6G, iron oxide nanoparticles, and MitoTracker Orange CMTMRos (Invitrogen, Carlsbad, CA, now Thermo-Fisher Scientific, Cambridge, MA).
[0172] Mitochondria and 18 Combination with F-rhodamine 6G 18 F-rhodamine 6G (40–100 μCi in a volume of 20 μl) was diluted to a volume of 1.0 mL with mitochondrial isolation solution A (homogenization buffer: 300 mM sucrose, 10 mM K-HEPES, and 1 mM K-EGTA, pH 7.2) at 4 °C, and then the isolated mitochondria (1 × 107 ~1×10 8 The mixture was thoroughly mixed with 0.5 ml of mitochondrial isolation solution A containing 18 F-rhodamine 6G electrophoretically distributed into the mitochondrial matrix in response to an electrical potential across the inner mitochondrial membrane and was therefore taken up by functional mitochondria. The mixture was incubated on ice for 10-30 minutes. The mixture was washed three times by centrifugation at 9,000 rpm (10,000 g) for 10 minutes, resuspending the pellet each time in mitochondrial isolation solution A. Following the final wash, the pellet was resuspended in respiration buffer.
[0173] Combining mitochondria with iron oxide nanoparticles via the outer mitochondrial membrane Iron oxide nanoparticles (10 mg) containing succinimidyl esters were suspended in respiration buffer at 4°C and then added to isolated mitochondria (1 × 10 7 ~1×10 8 The mixture was thoroughly mixed with 1.0 ml of 1000 mM NaCl containing 1% ammonium hydroxide (NaOH). Iron oxide was attached to mitochondrial amine groups on the outer mitochondrial membrane via succinimidyl ester amine reaction. The mixture was incubated on ice for 10-30 minutes. The mixture was washed three times by centrifugation at 9,000 rpm (10,000 g) for 10 minutes, and the pellet was resuspended each time in Mitochondria Isolation Solution A. Following the final wash, the pellet was resuspended in respiration buffer.
[0174] Combining mitochondria with two pharmaceutical agents 18 F-rhodamine 6G (40-100 μCi in a volume of 20 μl) and iron oxide nanoparticles containing succinimidyl ester (10 mg) were combined and diluted to a volume of 1.0 mL with mitochondria isolation solution A at 4 °C, followed by addition of isolated mitochondria (1 × 10 7 ~1×10 8The mixture was thoroughly mixed with 0.5 ml of mitochondrial isolation solution A. The mixture was incubated on ice for 10-30 minutes. The mixture was washed three times by centrifugation at 9,000 rpm (10,000 g) for 10 minutes, and the pellet was resuspended each time in mitochondrial isolation solution A. Following the final wash, the pellet was resuspended in respiration buffer.
[0175] Combining mitochondria via thiols MitoTracker® fluorophore (5 μmol / L; Invitrogen, Carlsbad, CA, now Thermo-Fisher Scientific, Cambridge, MA) was mixed with isolated mitochondria (1.0 mL) in respiration buffer. When the probes were mixed with functional mitochondria, they were oxidized and then reacted with thiols on proteins and peptides on the mitochondria to form conjugates. The mixture was incubated on ice at 4°C for 10 minutes in the dark. The mixture was washed three times by centrifugation at 9,000 rpm (10,000 g) for 10 minutes, with the pellet being resuspended each time in Mitochondria Isolation Solution A. Following the final wash, the pellet was resuspended in respiration buffer.
[0176] Example 3: Imaging An experiment was performed to demonstrate the imaging use of combined mitochondrial agents.
[0177] Animal models New Zealand White rabbits (Millbrook Farm, Amherst, MA) were used in the experiments. Experiments were approved by the Harvard Medical School Institutional Animal Care and Use Committee and conformed to the National Institutes of Health (NIH) guidelines for the care and use of laboratory animals (NIH Publication No. 5377-3, 1996). All studies were conducted in accordance with the American Physiological Society's principles for the care and use of animals.
[0178] The rabbit was sedated with intramuscular acepromazine (0.5 mg / kg im). A 22-gauge intravenous (iv) catheter was inserted into a marginal ear vein and secured with tape, and the rabbit was given an injection of 35 mg / kg ketamine and 2.5 mg / kg (iv) xylazine. This intravenous line was also used during surgery to administer heparin and lactated Ringer's solution at 10 ml kg -1 h -1 Heparin was injected (3 mg / kg iv via an intravenous line).
[0179] The thoracic cavity was then opened via a median sternotomy, the pericardial sac was exposed and opened to form a pericardial cradle, and the animals were euthanized under deep anesthesia by exsanguination after removal of the heart.
[0180] The isolated hearts were placed in a bath of Krebs-Ringer solution (100 mmol / l NaCl, 4.7 mmol / l KCl, 1.1 mmol / l KH2PO4, 1.2 mmol / l MgSO4, 25 mmol / l NaHCO3, 1.7 mmol / l CaCl2, 11.5 mmol / l glucose, 4.9 mmol / l pyruvate, and 5.4 mmol / l fumarate) at 4°C. The hearts were then subjected to Langendorff retrograde perfusion for 10 minutes to flush out the blood.
[0181] Ischemia and reperfusion The left anterior descending artery (LAD) was located, and a prolene (3-0) thread (Ethicon, Somerville, NJ) was threaded around the artery using a tapered needle. Both ends of the prolene thread were threaded through a small vinyl tube to form a snare. The coronary artery was occluded by pulling the snare, which was then secured by clamping the tube with mosquito clamps. Regional ischemia was visually confirmed by focal cyanosis of the myocardial surface. Reperfusion was achieved by removing the snare.
[0182] In contrast, global ischemia was achieved by cross-clamping the perfusion line on a Langendorff retrograde perfusion apparatus, and reperfusion was achieved by removing the cross-clamp.
[0183] For imaging, ischemia was induced for 20 minutes. For functional and infarct size studies, focal ischemia was induced for 30 minutes.
[0184] Administration 1×10 8 Dual-labeled mitochondria were either injected into the at-risk region of the heart of Langendorff rabbits or perfused into their coronary arteries.
[0185] At the beginning of reperfusion, the at-risk area of the Langendorff rabbit heart was injected with several injections of sterile respiratory buffer (control group) or 1 × 10 7 Each mouse received several injections of sterile respiratory buffer (injection group) containing 1 x 10 mitochondria / ml. 8Mitochondria were injected into the risk zone. Injections were performed using a sterile 1 ml insulin syringe with a 28-gauge needle. For the control group, respiratory buffer without mitochondria was injected into the risk zone.
[0186] In the third group, a total of 1 × 10 8 The mitochondria were perfused into the coronary artery (perfusion group).
[0187] PET Imaging was performed using a Siemens Focus 120 MicroPET scanner. Data were acquired for 60 minutes and reconstructed into a single image. Reconstruction was performed using unweighted OSEM2D to generate images. Image analysis was performed using the ASIPro software package (Siemens Medical Solutions).
[0188] MRI Imaging and T2 * To acquire relaxation times, the heart was placed on a BioSpec 70 / 30 USR 7T MRI System (Bruker) operated with ParaVision Version 5.1 software or a BioSpec 4.7T MRI system (Bruker) operated with ParaVision Version 4.0. After an initial positioning scan, multislice FLASH cine images were acquired. Images were reconstructed, and intensity data were analyzed using ImageJ software.
[0189] Micro-CT Micro-CT was performed using an Albira Preclinical Imaging System (Bruker) running Albira Software Suite version 1.530. Excised hearts were scanned using 600 projections per scan at an X-ray tube voltage and current of 45 kV and 400 μA, respectively. Reconstructed images were 512 × 512 × 512 voxels with an isotropic voxel size of 125 μm. SPIO gradient images were analyzed using the Amide software package (http: / / amide.sourceforge.net). Cross-sectional and volume-rendered images were generated using VolView, version 3.4 (Kitware).
[0190] Fluorescent staining of cardiac tissue Tissue samples for histochemical and microscopic studies were collected approximately 30 minutes after the onset of ischemia.
[0191] Transmyocardial samples were embedded and dissected from the risk region in the left ventricular free wall. Tissue samples were completely sectioned (5-7 μm thick) and then mounted on glass slides. Slides were baked overnight at 65°C, deparaffinized in xylene, rehydrated through a graded ethanol series, and subjected to antigen retrieval by heating three times for 5 minutes in 1 mmol / L ethylenediaminetetraacetic acid (pH 8.0) using a 700W microwave oven set on high. Slides were immunohistochemically stained with the following antibodies:
[0192] Injected heart sections were immunofluorescently stained for desmin (green) and the human-specific mitochondrial marker MTC02 (red) (anti-mitochondrial mouse monoclonal antibody [MTC02] (human-specific), Abcam, Cambridge, MA), wheat germ agglutinin (red), and the human mitochondrial marker 113-1 (green). Nuclei were identified using the DNA-binding dye 4',6-diamidino-2-phenylindole (DAPI) (blue) (Invitrogen, Carlsbad, CA, now Thermo-Fisher Scientific, Cambridge, MA). Perfused hearts were immunostained with α-actinin (red) and MTC02 (green) (anti-mitochondrial mouse monoclonal antibody [MTC02] (human-specific), Abcam, Cambridge, MA), or with Prussian blue staining for lectin (green) and 113-1 (red) or iron (blue) and pararosaniline counterstain (pink). Some hearts were perfused with lectin and then fixed to reveal the luminal vascular surface. MTC02 and nuclear staining were shown with phase contrast illumination.
[0193] Other antibodies used were human-specific anti-MTC02 rabbit polyclonal antibody (ab91317, Abcam, Cambridge, MA), human-specific anti-mitochondrial mouse monoclonal antibody [113-1] (ab92824, Abcam, Cambridge, MA), and human-specific anti-MTC02 rabbit monoclonal antibody [EPR3314] (ab79393, Abcam, Cambridge, MA).
[0194] result At the beginning of reperfusion, 1 × 10 8The hearts were injected (Figure 2A) or perfused (Figure 2B) with double-labeled mitochondria. The top row of Figures 2A and 2B displays volume renderings of each heart, with micro-computed tomography (μCT), positron emission tomography (PET), and composite renderings shown from left to right. The metal suture (bright signal in μCT) indicates the site of left anterior descending (LAD) coronary artery ligation. The middle row of Figures 2A and 2B is a single coronary slice of the heart, with magnetic resonance imaging (MRI), PET, and composite images depicted from left to right. The bottom row of images in Figures 2A and 2B is a single transverse slice of the injected or perfused heart, with MRI, PET, and composite images depicted from left to right. The hypointense T2 * The area of the MRI signal is 18 This correlates with the PET signal derived from F-rhodamine 6G. These figures also show that coronary perfusion of exogenous mitochondria resulted in widespread distribution of these organelles throughout the heart.
[0195] Rabbit hearts subjected to global ischemia 18 F-rhodamine 6G-labeled mitochondria showed a similar distribution.
[0196] Figures 3A and 3B show histological staining of ischemic hearts injected and perfused with human mitochondria, respectively. Injected heart sections (Figure 3A) were immunofluorescently stained for desmin (green) and the human-specific mitochondrial marker MTC02 (red) (top row). The left center row shows staining with wheat germ agglutinin (red) and the human mitochondrial marker 113-1 (green). Nuclei are identified using the DNA-binding dye 4,6-diamidino-2-phenylindole (DAPI) (blue). MTC02 and nuclear staining are shown with phase-contrast illumination (bottom row). Transplanted mitochondria associated with the cardiomyocyte membrane are indicated by arrows (left); however, the majority of injected organelles remained in the interstitial space. Perfused hearts (Figure 3B) were immunostained for α-actinin (red) and MTC02 (green) (top row). Transplanted mitochondria are indicated by arrows. Several hearts were perfused with lectin and then fixed to reveal the luminal vascular surface. The right-center row shows lectin (green) and 113-1 (red) staining; whereas the bottom row shows Prussian blue staining for iron (blue) and pararosaniline counterstain (pink). These figures show that mitochondria were typically found in the interstitial space; however, some perfused mitochondria were associated with the vasculature or internalized into cardiomyocytes.
[0197] Example 4: Therapeutic Use of Combined Mitochondrial Agents Further experiments were performed in the animal model described in Example 3 using unlabeled, autologous liver mitochondria to determine the cardioprotective effects of delivering combined mitochondrial agents to the ischemic heart.
[0198] Tetrazolium test (TTC) and infarct size measurement Triphenyltetrazolium chloride was used to distinguish metabolically active from metabolically inactive tissue. In a typical tetrazolium test, the white compound is enzymatically reduced to the red TPF (1,3,5-triphenylformazan) in live tissue due to the activity of various dehydrogenases (enzymes important in the oxidation of organic compounds and therefore in cellular metabolism), whereas in necrotic areas, these enzymes are either denatured or degraded, leaving behind the white TTC. For this reason, TTC has been employed in autopsy pathology to aid in the postmortem identification of myocardial infarction. Healthy, viable myocardium stains deep red from cardiac lactate dehydrogenase; whereas, potentially infarcted areas will be paler.
[0199] Tissue samples for histochemical and microscopic studies were collected approximately 150 minutes after the onset of ischemia. The area at risk (AAR) was defined by injection of monastril blue pigment into the aorta. Hearts were rapidly removed and sliced transversely across the long axis of the LV from apex to base into 1-cm-thick sections, which were then traced under room light onto transparent acetate sheets covering glass plates. The sliced hearts were incubated in 1% triphenyltetrazolium chloride (Sigma Chemical Co., St. Louis, MO) in phosphate buffer (pH 7.4) at 38°C for 20 minutes. Copies of the stained cardiac slices were traced under room light onto transparent acetate sheets covering glass plates. The areas of the AAR and infarct size (IS) within the LV were measured by planimetry. The infarct zone and AAR volumes were calculated by multiplying the planimetric area by the slice thickness. The ratio of ARR to LV weight was calculated. Infarct size was expressed as a percentage of the AAR per heart (IS / AAR). Detailed methods are described in Wakiyama H, Cowan DB, Toyoda Y, Federman M, Levitsky S, McCully JD. Selective opening of mitochondrial ATP-sensitive potassium channels during surgically induced myocardial ischemia decreases necrosis and apoptosis, Eur J Cardiothorac Surg. 21:424-433. doi: 10.1016 / S1010-7940(01)01156-3(2002), which is incorporated herein by reference.
[0200] result Mitochondrial transplantation by intravascular injection before reperfusion significantly reduced myocyte necrosis and significantly enhanced postischemic function (Figure 4). To quantify the extent of myocardial injury, infarct size was biochemically measured using TTC staining. Absolute measurement of infarct size by TTC staining revealed no significant difference in the size of the area at risk (i.e., the area ischemic due to LAD occlusion) between the control and perfusion groups (Figure 4). However, myocardial infarct size, expressed as a percentage of the area at risk, was significantly reduced (P<0.05) in mitochondria-treated hearts compared to controls (Figure 4). Figure 5 shows regional myocardial function in the ischemic region as assessed by regional myocardial systolic shortening using three piezoelectric ultrasound transducers. This confirms that mitochondria can provide cardioprotection against ischemia and reperfusion injury.
[0201] Example 5: Rescue of mitochondrial function and mtDNA replacement Experiments were performed to determine whether administering mitochondria to cells could rescue mitochondrial function and replace damaged mitochondrial DNA.
[0202] method Hela P 0 The cells are able to generate energy through fermentation, but lack the ability to consume oxygen due to the depletion of electron transport chain proteins encoded by mtDNA. 0 It is designed to restore mitochondrial function in cells.
[0203] Mitochondria were isolated from HeLa cells containing intact mtDNA and then 18 The cells were then labeled with F-rhodamine 6G and 30 nm iron oxide nanoparticles. 0 Cells were co-incubated with these mitochondria.
[0204] Detailed methods are described in Pacak CA, Preble JM, Kondo H, Seibel P, Levitsky S, del Nido PJ, Cowan DB and McCully JD, Actin-dependent mitochondrial internalization in cardiomyocytes: evidence for rescue of mitochondrial function. Biol Open 4, 622-626. PMC4434813(2015), which is incorporated herein by reference in its entirety.
[0205] result ATP content was measured in HeLa cells after 24, 48, 72 h and 1 and 2 weeks of co-incubation with mitochondria. 0 The enhanced intracellular ATP content was significantly increased in HeLa cells after mitochondrial internalization. 0 This corresponded to a significant increase in the rate of cellular oxygen consumption.
[0206] PCR analysis demonstrated the replacement of mtDNA in HeLa p0 cells after mitochondrial transplantation. The results showed that HeLa p0 cells co-incubated with HeLa cell mitochondria (containing intact mtDNA) 0 Although the absolute amount of mtDNA in the cells is significantly lower than that observed in HeLa cells, the mtDNA present does not significantly affect the intracellular ATP content and oxygen consumption rate compared with untreated HeLa cells. 0 It is sufficient to significantly enhance the expression of the IgG compared to the normal cells.
[0207] Taken together, the results suggest that mitochondrial transplantation has the potential to rescue cellular function and replace damaged mitochondrial DNA.
[0208] Example 6: Human Patient Treatment An effective amount of isolated mitochondria was administered to two clinically active patients on extracorporeal membrane oxygenation (ECMO) or extracorporeal life support (ECLS) to evaluate the therapeutic efficacy of such treatment. For each case, approximately 8-10 separate injections of approximately 100 microliters (1 x 10 in respiratory buffer) were administered. 7 The mitochondrial membrane protein (containing 100% mitochondria) was delivered to the at-risk areas (anterior and posterior) of the left ventricle. All of these procedures were reviewed and approved by an Institutional Review Board. On a case-by-case basis, it was determined that the risks associated with these procedures could be justified by the expected benefits.
[0209] Case Report 1 A 9-day-old male infant with significant comorbidities was placed on extracorporeal membrane oxygenation (ECMO) due to surgical complications of coronary insufficiency. On the 9th day of ECMO, the patient underwent surgery for coronary artery repair. After surgical repair, the patient was returned to the Cardiac Intensive Care Unit (CICU) under ECMO support.
[0210] The patient remained on ECMO support but could not be weaned from ECMO. On Day of Life (DOL) 19, the rectus muscle was harvested for autogenous mitochondrial isolation. Mitochondria were injected into the myocardium along the anterior and lateral aspects of the left ventricle (LV) and into areas of hypocontractility. The patient tolerated both the procedure and the placement of pacing wires. The chest was left open, disinfected, and dressed. The patient remained stable overnight under ECMO. The patient could not be decannulated, and a second mitochondrial transfer was completed on DOL 21. The rectus muscle was biopsied again, and the mitochondria were processed. Mitochondria were then injected in 10 separate injections of approximately 100 microliters each. Each injection (1 x 10 in respiration buffer) 7 0.1 mL containing 1000 mitochondria was delivered to the risk area of the left ventricle.
[0211] The next day, the patient was able to tolerate an ECMO weaning trial, and an epicardial echocardiogram showed strong RV and good LV function with a low flow rate of 50 mL / kg / min. However, the patient was unable to tolerate complete clamping of the circulation, and there continued to be ongoing concerns about pulmonary, renal, and hepatic organ failure. On DOL 23, after discussion with the family, a decision was made to change care.
[0212] Case report 2 The second patient was a 2-year-old girl with tricuspid atresia type 1B with pulmonary valve stenosis (PS) and ventricular septal defect (VSD) who had a history of VACTERL syndrome (vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities) and a history of complex cardiac surgery. She presented for staged palliation of a single ventricle. The intraoperative course was complicated by multiple cardiopulmonary bypass (CPB) sessions due to low oxygenation and ventilation and reduced right pulmonary artery (RPA) blood flow. Postoperative transesophageal echocardiogram (TEE) revealed ventricular function fluctuating between normal and moderately depressed. She was stabilized and transferred to the cardiac intensive care unit (CICU) with open chest and mechanical ventilation.
[0213] On postoperative day (POD) 1, myocardial function deteriorated, and she was cannulated onto extracorporeal membrane oxygenation (ECMO). Angiography revealed near-total occlusion of the left anterior descending coronary artery (LAD), with coronary flow restored by surgical intervention. The patient was returned to the CICU on full-flow ECMO support and remained critically ill but stable. On POD 3, the patient was returned to the catheterization laboratory for repeat evaluation of the LCA. Again, no significant flow through the left main coronary artery (LMA) was confirmed. The LMA was stented and dilated, and repeat angiography revealed restoration of blood flow to the LMA and LAD. On POD 4, an echocardiogram revealed mild MR, mild aortic regurgitation (AR), and severe widespread LV dysfunction. The patient remained critically ill but stable on ECMO support.
[0214] On POD 5, the patient still demonstrated severe LV dysfunction on echocardiogram. The decision was made to proceed with autogenous mitochondrial implantation concomitant with chest lavage, hematoma evacuation, and new atrial lead placement. Following all clinical procedures, a TEE was completed, confirming LV dysfunction approximately along the posterior free wall. A rectus muscle biopsy was performed, and mitochondria were harvested from the tissue. Mitochondria were administered at a dose of 1 × 10 per injection. 7 The dose was divided into 10 separate injections of 100 microliters each containing mitochondria. Injections into the failing myocardium were given at several sites (five injections anteriorly and five injections along the posterior left ventricle). The patient tolerated the injections well, with no evidence of electrical disturbances or intramural hematomas as determined by electrocardiogram (ECG) or evidence of arrhythmias as determined by echocardiogram.
[0215] On POD 7, a repeat catheterization showed at least moderate LV dysfunction; notably, the LCA stent was stable and blood flow through both coronary arteries was good. The patient was decannulated from ECMO the next day in a state of stable moderate dysfunction. On POD 14, functional improvement to mild dysfunction was noted without mitral regurgitation (MR) or AR, with continued good flow through the stent. Cardiac function remained stable with mild dysfunction until the patient's discharge on POD 38.
[0216] Example 7: High-resolution microscopy We performed experiments to image mitochondrial fusion in cardiac cells and demonstrate the fusion mechanism. We used 3D super-resolution microscopy to study mitochondrial internalization in human iPS-derived cardiomyocytes and primary human cardiac fibroblasts.
[0217] Mitochondria in human fibroblasts were labeled using a mitochondrial-specific baculovirus vector for green fluorescent protein (GFP). Mitochondria in human iPS cardiac cells were labeled using a mitochondrial-specific baculovirus vector for red fluorescent protein (RFP).
[0218] GFP-labeled mitochondria were then isolated from BacMam 2.0-infected human fibroblasts, and these organelles were incubated with cardiac fibroblasts containing RFP-labeled mitochondria. The isolated mitochondria retained their membrane potential as determined by incubation with MitoTracker Red CMXRos and were reactive with anti-human mitochondrial antibodies. The experiments confirmed that the isolated mitochondria produced ATP and possessed the respiratory capacity required for internalization and function. After 2 or 4 hours, cells were fixed and mounted to assess whether super-resolution structured illumination microscopy (SR-SIM) could resolve the subcellular location of internalized mitochondria. The experiments showed that exogenous mitochondria were rapidly internalized into human cardiac fibroblasts (HCFs) and colocalized with the mitochondrial network of recipient fibroblasts. To establish whether endocytosed mitochondria integrated with the mitochondrial network in recipient cardiac fibroblasts, equivalent experiments were performed on human cardiac fibroblasts using three of the four available laser lines.
[0219] Rotation of volume renderings of SR-SIM images revealed what appeared to be exogenous mitochondria fusing with the endogenous mitochondrial network of recipient fibroblasts. A more extensive analysis of a similar experiment using iCell® cardiomyocytes (iCell-CMs) (Figures 6A-6D) confirmed the fusion of exogenous fibroblast-derived mitochondria containing targeted GFP with the endogenous organelle network over a 4-hour period. Figures 6A-6D show 3D volume renderings of mitochondrially targeted RFP-expressing cardiomyocytes treated with isolated GFP mitochondria for 0.5, 1, 2, and 4 hours. The fusion of exogenous mitochondria with the endogenous mitochondrial network is readily apparent (Figure 6A shows the red channel, Figure 6B shows the green channel, Figure 6C shows the blue channel, and Figure 6D shows the merged image).
[0220] These results provided strong evidence for the feasibility of using SR-SIM to unambiguously determine the location of internalized mitochondria in cells and confirmed the fusion of exogenous and endogenous mitochondria.
[0221] To confirm and quantify this observation, we used fluorescence-activated cell sorting (FACS). After verifying that isolated mitochondria could be analyzed using flow cytometry, GFP-labeled mitochondria from infected HCFs were added to iCell-CM containing RFP-labeled mitochondria for 4 hours. By washing these cells and then isolating the entire mitochondrial population, we observed mitochondria that emitted both red and green fluorescence (Figures 7A-7D). In Figures 7A-7D, green fluorescence is shown on the X-axis and red fluorescence is shown on the Y-axis (logarithmic scale), respectively. The control group represents unlabeled mitochondria, and the GFP- and RFP-mitochondrial groups were isolated from infected HCFs. Total mitochondria were isolated from iCell-CM expressing RFP-mitochondria (endogenous) that had been treated with isolated HCF GFP-labeled mitochondria (exogenous) for 4 hours. Mitochondrial fusion was evident in organelles that were fluorescent in both the green and red channels. These experiments showed that 18.1% of exogenous mitochondria were fused with endogenous mitochondria over 4 hours. Clearly, endogenous mitochondria (both labeled and unlabeled) far outnumber exogenous mitochondria; however, experiments demonstrated that only a few organelles were necessary to induce improvement in cardiac function.
[0222] Because the results indicated that a significant number of exogenous mitochondria had integrated with the endogenous mitochondrial network, other cellular compartments were examined to understand the point at which these organelles escape the endosomal-lysosomal system. To maximize the information obtained by SR-SIM, all four available laser lines were used. To test the ability to read the red, green, blue, and far-red channels in a single acquisition, iCell-CMs were infected with BacMam 2.0 CellLight™ RFP-mitochondria and 1 × 10 cells were cultured. 7 Cardiomyocytes were treated with GFP-labeled HCF mitochondria for 4 hours. Following treatment, the cardiomyocytes were washed and stained with 4',6-diamidino-2-phenylindole (DAPI) and antibodies against α-actinin (ACTN), which were detected with an Alexa 633-conjugated secondary antibody. This study demonstrated that using a combination of fluorescent protein expression and antibody detection, a great deal of information can be extracted from each acquisition and the identities of various cellular compartments and structures can be determined.
[0223] Using this strategy, we investigated endosomal escape by treating cardiomyocytes with isolated mitochondria for 1 hour. iCell-CMs were first infected with RFP-Early Endosome or RFP-Late Endosome CellLight™ reagent and then treated with GFP-labeled mitochondria isolated from HCFs. Internalized exogenous mitochondria were endocytosed into acidic intracellular compartments via an actin-dependent mechanism. In addition to employing CellLight™ reagent, we used an anti-human mitochondrial antibody (MTC02) to confirm that the green fluorescent spheres were internalized mitochondria.
[0224] The results showed that at 1 hour, internalized mitochondria had passed through early endosomes and were contained within late endosomes. Four-channel super-resolution microscopy revealed the escape of GFP-labeled mitochondria from late endosomes, and all of these mitochondria reacted well with the MTC02 antibody.
[0225] Using SR-SIM and flow cytometry, we developed a proposed model of the endosomal pathway involved in mitochondrial internalization. Figure 8 shows a schematic representation of the intracellular fate of exogenous mitochondria. Isolated mitochondria enter cardiac cells (HCF and iCell-CM) via actin-dependent endocytosis. Internalized organelles rapidly progress from early endosomes (<0.5 h) to late endosomes, endolysosomes, and lysosomes (0.5–4 h). Established protein expression profiles can be used to identify each of these compartments (top of figure). Mitochondrial escape appears to occur primarily from the late endosomal compartment. The escaped exogenous mitochondria then fuse with endogenous mitochondria (indicated by arrowheads). Other internalized exogenous mitochondria are destined for degradation via the phagolysosomal pathway.
[0226] Collectively, the results demonstrated that mitochondria enter cells by endocytosis. These organelles either escape from early endosomes, late endosomes, and endolysosomes or are degraded through the lysosomal and phagolysosomal pathways. Exogenous mitochondria that escape from the endosomal compartment subsequently fuse with the endogenous cardiomyocyte mitochondrial network. The time frame for uptake is >30 min. The results further demonstrated that 3D super-resolution structured illumination microscopy can be used with labeled mitochondria for various imaging purposes.
[0227] Example 8: Coronary Infusion and Blood Flow The examples of the present disclosure demonstrate that mitochondria can be delivered to the heart through the vasculature. Intravascular delivery of mitochondria through the coronary arteries results in mitochondrial delivery and uptake throughout the heart 10 to 30 minutes after injection. This contrasts with direct injection of mitochondria into the heart itself, where mitochondria remain in the area where they are injected. Thus, while intravascular delivery of mitochondria allows for the distribution of mitochondria throughout the heart and provides a rapid method for providing and restoring energy to the entire heart, several concerns remain. When the heart is injured, the vasculature changes. These changes may affect the delivery or uptake of injected mitochondria. Mitochondria may not attempt to migrate to cardiac cells, but may become trapped in the vasculature due to their altered state and clog the vasculature. This can damage the heart by blocking blood flow to the heart, potentially leading to death. To address these concerns, experiments were performed to demonstrate that mitochondria do not alter cardiac blood flow.
[0228] In this example, all experiments were performed in a clinically relevant porcine model. Cardiac blood flow was measured, and then mitochondria or other agents were delivered via coronary vascular infusion. Blood flow was then measured again to determine any changes in blood flow. As shown in Figure 9, coronary arteries were constricted with vasopressin followed by epinephrine (Epi) to induce an increased heart rate. Adenosine was used to demonstrate vascular reactivity. These experiments were performed on both normal and injured hearts. Polystyrene beads were also used as a positive control. 3 um, 10 um, and 150 um polystyrene beads were used to block blood flow. No immune or autoimmune responses were observed throughout the experiment.
[0229] The results show that delivery of mitochondria via coronary injection does not alter blood flow or myocardial perfusion in normal or vasoconstricted hearts. Figures 10A-10C and 11A-11D show that heart rate or conductance does not change with intravascular delivery of mitochondria. These results demonstrated that there is no coronary obstruction after coronary injection of mitochondria. These results support the ease with which coronary injection of mitochondria can be used in cardiac surgery.
[0230] Additionally, delivery of mitochondria via intravascular injection significantly increased coronary blood flow without altering mean blood pressure or heart rate. Figures 12A-12B are a series of graphs showing the percentage of systolic shortening after coronary injection of various agents. Figures 13A-13B are a series of graphs showing coronary blood flow after coronary injection of various agents. Figures 12A-12B and 13A-13B show that coronary injection of mitochondria increases coronary blood flow. This response was greater than the response to drugs that can increase blood flow, such as adenosine, and overcame vasopressin-induced vasoconstriction. The ability to increase blood flow without increasing heart rate allows for clinical use in angina-type injuries and ischemia / reperfusion-related injuries, as well as in areas of tissue damage where increased blood flow and oxygen delivery are required.
[0231] The increase in coronary blood flow was also concentration-dependent and lasted approximately 5 minutes. Figure 14 shows that mitochondria enhanced vasodilation beyond that of adenosine, indicating that the vasodilatory effect of mitochondrial injection was immediate. The effect was also dependent on the length of time between mitochondrial isolation and administration. The vasodilatory effect decreased with increasing time since isolation (e.g., 30-60 minutes of storage). Therefore, mitochondria must be freshly isolated and viable. Dead or devitalized mitochondria are ineffective at increasing coronary blood flow (Figures 13A-13B and 14).
[0232] Figures 15A-15B further show coronary blood flow in response to different doses of mitochondria. 9mitochondria were used to achieve optimal coronary blood flow.
[0233] Example 9: Coronary Infusion to Treat Myocardial Injury Experiments were also performed to demonstrate the efficacy of mitochondrial delivery by vascular injection to limit myocardial damage and enhance myocardial function after experimentally induced reversible myocardial ischemia in a clinically relevant porcine model.
[0234] Pigs were subjected to either 15 minutes (stunning) or 30 minutes (ischemia / reperfusion injury) of focal ischemia, followed by 120 minutes of reperfusion (Figure 16). Comparisons between these groups provided a means of determining the effect of mitochondrial injection in a live tissue model (stunning) compared to a heterogeneous mixed cell (live and dead) population (ischemia / reperfusion injury).
[0235] Three groups were investigated for stunning and ischemia / reperfusion: two focal ischemia groups with LAD focal ischemia, and a sham control group in which the animals' snare was not clamped or immobilized, resulting in no focal ischemia. Following 15 or 30 minutes of focal ischemia, the snare was removed, and the heart received a single injection of 10 mL of sterile respiratory buffer (RI-vehicle and sham control) or mitochondria (1.7 × 10) administered antegrade through the angiography catheter into the left coronary ostium. 7 The animals received either a single injection of sterile respiratory buffer (10 mL) containing mitochondrial ischemia (RI-mitochondria) or RI-mitochondria (RI-mitochondria). The catheter was flushed with 10 mL of saline. The animals remained under anesthesia for 2 hours to allow reperfusion of the risk area. These experiments confirmed that intravascular injection of mitochondria reduced infarct size and enhanced functional recovery after ischemia in a clinically relevant porcine model (Figures 17A-17B, Figures 18A-18B).
[0236] Example 10: Immune Response Experiments were performed demonstrating the absence of B-cell or T-cell immune responses to single or multiple injections of autologous or allogeneic mitochondria at any concentration.
[0237] To demonstrate the immunogenicity of autologous and allogeneic mitochondria, 5-8 week-old female BALB / cJ (recipient and donor) and C57BL / 6J (donor) mice were used.
[0238] The first experiment was designed to determine the immune response to single or multiple injections of mitochondria. Three groups were investigated: mice were injected with 1 x 10 5 (n=10); 1×10 6 (n=10) or 1×10 7 Mice (n=10) received a single intraperitoneal (ip) injection (0.5-1.0 mL) containing either autologous mitochondria from BALB / cJ mice or allogeneic mitochondria from C57BL / 6J mice. To provide a positive control, mice received a single injection of allogeneic splenocytes isolated from C57BL / 6J mice. A separate group of mice (BALB / cJ, n=10) received a single i.p. injection (0.5-1.0 mL) of sterile respiratory medium as a control.
[0239] For single injections, mice were injected on day 0 and then allowed to recover for 10 days. Immune responses were assessed on day 10. For multiple injections, BALB / cJ mice were injected on days 6, 3, and 0 and then allowed to recover for 10 days. Immune responses were assessed on day 10. Figures 19A-19B show T cell responses to single and multiple doses of mitochondria. The results show that there was no T cell response to single or multiple doses of mitochondria at any concentration. Figure 20 shows B cell responses to single and multiple doses of mitochondria (*P<0.01 splenocytes vs. autologous mitochondria). The concentration of mitochondria was 1x10 7 organelles / ml, and the concentration of splenocytes was 2 x 10 7 The control was buffer solution. These results demonstrated the absence of a B cell response to single or multiple doses of mitochondria.
[0240] A second experiment was conducted to determine rejection and allogeneic responses. Five- to eight-week-old female BALB / cJ mice (recipient and donor) and C57BL / 6J (donor) received single and multiple intraperitoneal injections of mitochondria as described in the first experiment. On day 10, the mice received skin grafts from C57BL / 6J mice. Following skin grafting, the mice were followed for 20 days to determine skin graft rejection and immune responses. If mitochondria were capable of inducing an immune response, recipient mice would reject the grafted skin more quickly than mice receiving the vehicle (control). The results showed that mice receiving single or multiple doses of mitochondria did not reject the grafted skin more quickly than mice in the control group. Therefore, single or multiple doses of mitochondria do not induce a rejection response.
[0241] Example 11: Intracellular delivery of drugs Experiments were carried out to determine the optimal rhodamine 6G concentration, incubation time, and temperature at which isolated mitochondria could incorporate rhodamine 6G.
[0242] In this example, 2 x 10 7 of mitochondria were incubated with 0.325 uM, 0.65 uM, 1.25 uM, and 2.5 uM rhodamine 6G. After 15, 30, 45, and 60 minutes of incubation at either 4° C. or 26° C., the bound and unbound fractions of rhodamine 6G were determined (FIG. 21).
[0243] Figures 22A-22B, 23A-23B, 24A-24B, and 25A-25B show that when mitochondria are incubated with 2.5 μM rhodamine 6G at 26°C, 60 minutes is significantly inferior to 15 minutes. When mitochondria are incubated with 1.25 μM rhodamine 6G at 5°C, 30 minutes, 45 minutes, and 60 minutes are all significantly superior to 15 minutes. Furthermore, there is a significant difference between incubation temperatures of 4°C and 26°C for 30 and 60 minutes of incubation with either 2.5 μM or 1.25 μM rhodamine 6G. The bound fraction of rhodamine 6G at 4°C is 9-13%, while the bound fraction at 26°C is 3-8%. In summary, under optimal conditions, approximately 0.15 μM of rhodamine 6G reacts with 2 × 10 7 of mitochondria, and for 2.5 uM rhodamine 6G, approximately 0.3 uM rhodamine 6G binds to 2 x 10 7 binds in the mitochondria.
[0244] Furthermore, 2 × 10 7 For mitochondria, the optimal conditions are 2.5 uM rhodamine 6G incubated at 4°C for 30 minutes.
[0245] This example demonstrated that mitochondria can be used as carriers for the intracellular delivery of drugs.
[0246] Example 12: Adoptive mitochondrial transfer enhances endothelial cell engraftment Stem cell integration and angiogenesis are major obstacles to the therapeutic potential of stem cells. Experiments were performed showing that adoptive mitochondrial transfer enhances endothelial cell engraftment.
[0247] Isolation and culture of human endothelial colony forming cells (ECFCs) Melero-Martin, JM, Melero-Martin, JM, Khan, ZA, Khan, ZA, Picard, A., Picard, A., et al. (2007). In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Human ECFCs were isolated from umbilical cord blood samples according to an Institutional Review Board-approved protocol as described in Blood, 109(11), 4761-4768. ECFCs were cultured on 1% gelatin-coated plates using ECFC medium: EGM-2 (Lonza) supplemented with 20% FBS and 1x GPS, excluding hydrocortisone. All experiments were performed on ECFCs at passages 5–8.
[0248] Isolation and culture of human mesenchymal stem cells (MSCs) Lin, R.-Z., Moreno-Luna, R., Moreno-Luna, R., Munoz-Hernandez, R., Munoz-Hernandez, R., Li, D., et al. (2013). Human white adipose tissue vasculature contains endothelial colony-forming cells with robust in vivo vasculogenic potential. Human MSCs were isolated from normal discarded subcutaneous white adipose tissue obtained during clinically indicated procedures according to an institutional review board-approved protocol as described in Angiogenesis, 16(4), 735-744. Human MSCs were cultured in uncoated plates using MSCGM (Lonza) supplemented with 10% MSC-qualified FBS (Hyclone) and 1x glutamine-penicillin-streptomycin (GPS; Invitrogen). All experiments were performed on MSCs at passages 4–6.
[0249] Isolation of mitochondria from ECFCs ECFCs (9 × 10) were isolated from the culture. 6 Cells (1000 cells) were harvested and resuspended in 800 μL of Reagent A from the Mitochondria Isolation Kit for Cultured Cells (Thermo Scientific). Cells were lysed on ice for 30 seconds using a Dounce Homogenization Kit (VWR). The cell lysate was mixed with 800 μL of Reagent C and then centrifuged at 700 g for 10 minutes at 4°C. The supernatant was transferred to a new tube and centrifuged at 12,000 g for 15 minutes at 4°C. After centrifugation, the pellet was resuspended in 500 μL of Reagent C and centrifuged again at 12,000 g for 15 minutes at 4°C. The final pellet contained isolated mitochondria ready for import.
[0250] Mitochondrial import into ECFCs The isolated mitochondria were resuspended in 1 mL of ECFC medium and added directly to 9 × 10 ECFCs in culture. 6 Using mitochondria isolated from ECFCs, 3 x 10 6 Mitochondria were transferred into ECFC cells (donor to recipient ratio 3:1). Five hours after mitochondrial transfer, the medium was refreshed with fresh ECFC medium, and the recipient ECFCs were then immediately used for in vivo transplantation experiments. Recipient ECFCs are referred to as ECFC-Mito, and control ECFCs that did not receive exogenous mitochondria are referred to as ECFC control.
[0251] In vivo transplantation of ECFCs into immunodeficient nude mice Animal experiments were performed in an AAALAC-approved facility under protocols approved by the Institutional Animal Care and Use Committee at Children's Hospital Boston. Human ECFCs (2 × 10) were resuspended in 200 μL of collagen-fibrin-laminin gel. 5 cells; with or without mitochondrial transfer) and MSCs (3 × 10 5Cells were injected subcutaneously into the backs of 6-week-old male athymic nu / nu mice (Massachusetts General Hospital, Boston, MA). Mice were euthanized and the implants were harvested 7 days later.
[0252] Histology, immunohistochemistry, and immunofluorescence Implants were harvested 7 days later. Explants were fixed overnight in 10% buffered formalin, paraffin-embedded, and sectioned (7 μm thick). Hematoxylin and eosin (H&E)-stained sections were examined for the presence of vasculature using ImageJ 1.47v software (National Institutes of Health). H&E-stained sections were examined for the presence of blood vessels containing red blood cells. For immunostaining, sections were deparaffinized and antigen retrieval was performed in Tris-EDTA buffer (10 mM Tris-Base, 2 mM EDTA, 0.05% Tween-20, pH 9.0). Sections were then blocked in 5–10% blocking serum for 30 minutes and incubated with mouse anti-human CD31 primary antibody (1:50; Abcam) at room temperature for 1 hour. Detection of hCD31 was performed using a horseradish peroxidase-conjugated mouse secondary antibody (1:200; Vector Laboratories) and 3,3'-diaminobenzidine (DAB), followed by hematoxylin counterstaining and Permount mounting. Fluorescent staining was performed using rhodamine-conjugated UEA-1 (1:200), followed by DAPI counterstaining (Vector Laboratories).
[0253] microvessel density The mean number of red blood cell-filled vessels (vessels / mm) in H&E-stained sections from the center of the implant 2 Microvessel density was reported as the mean ± standard error of the mean (SEM) obtained from four individual implants. The entire area of each section was analyzed.
[0254] Microscopy Images were taken using an Axio Observer Z1 inverted microscope (Carl Zeiss) and AxioVision Rel. 4.8 software. Fluorescent images were taken with an ApoTome.2 Optical sectioning system (Carl Zeiss) and a 40× / 1.4 oil objective. Non-fluorescent images were taken with an AxioCam MRc5 camera using a 40× / 1.4 oil objective.
[0255] statistical analysis Data were expressed as mean ± standard error of the mean (SEM). Means were compared using an unpaired Student's t-test. All statistical analyses were performed using GraphPad Prism v.5 software (GraphPad Software Inc.). P < 0.05 was considered statistically significant.
[0256] result Mitochondria were isolated from donor ECFCs and transferred into recipient ECFCs at a donor-to-recipient ratio of 3:1. The isolated mitochondria were allowed to be absorbed by the recipient ECFCs for 5 hours. The recipient ECFCs that received the exogenous mitochondria (ECFC-Mito) were then transplanted into mice to evaluate their angiogenic potential (Figure 26).
[0257] ECFCs and MSCs were resuspended in collagen hydrogel and then subcutaneously injected into the backs of immunodeficient nude mice (Figure 27A). Figure 27A shows an in vivo angiogenesis assay. Figure 27B shows explants harvested 7 days after transplantation. The top image shows ECFC-Mito (2 x 10 5 cells) and MSCs (3 × 10 5 ECFC control (2 × 10 cells) 5 cells) and MSCs (3 × 10 5 Implants containing 100% erythrocytes (cells) served as controls.
[0258] H&E images show that red blood cell-filled vessels are abundant in the implants containing ECFC-Mito but not in the implants containing the ECFC control (Figure 28A). Microvessel density revealed higher vascular density in the implants containing ECFC-Mito than in the implants containing the ECFC control (Figure 28B). In Figure 28B, bars represent the mean ± SEM (n = 4), and the difference was statistically significant (*P < 0.05).
[0259] Recipient ECFCs that received exogenous mitochondria (ECFC-Mito) lined the lumen of newly formed perfused human blood vessels. Binding of rhodamine-conjugated UEA-1 lectin demonstrated the formation of a human-specific vascular lumen in ECFC-Mito-containing implants (Figure 29A). Notably, UEA-1 lectin binds with high affinity to human endothelium, but not to murine endothelium. Human-specific CD31 (h-CD31) immunostaining confirmed the construction of a vascular lumen by the transplanted human ECFC-Mito (Figure 29B).
[0260] These experiments demonstrate that treating cells with mitochondria enhances cell engraftment, it enhances angiogenesis in stem cells, and it enhances cell survival in vivo.
[0261] Example 13: Pulmonary ischemia / reperfusion injury Experiments were performed showing that mitochondria delivered by intravascular injection through the pulmonary artery were localized within the lung.
[0262] Mice were anesthetized and placed on a ventilator. 18 F-rhodamine 6G-labeled mouse mitochondria were injected into the main pulmonary artery (visualized via sternotomy). Images were acquired 20 minutes later by PPET and μCT using an Alvira PET / SPECT / CT Imaging System (Bruker, Billerica, MA). Images demonstrate that delivery of mitochondria to the pulmonary artery of mice results in distribution throughout the lung (Figures 30A-30B).
[0263] In separate experiments, the middle and lower lobes of the right lung of mice were clamped for 1 hour (middle) and 2 hours (lower) of ischemia. After unclamping (reperfusion), the mice were treated with buffer or isolated mitochondria. Mice were evaluated 48 hours after reperfusion. Results show that delivery of intact, viable mitochondria reduced lung ischemia-reperfusion injury in a mouse model, and that mitochondria preserved lung structure and function after ischemia / reperfusion.
[0264] In a separate experiment, mice were anesthetized and placed on a ventilator. The left hilar structure was clamped for 2 hours. Buffer solution or 3 cc (cubic centimeter) of mitochondrial solution was injected into the left pulmonary artery, and the mice were sacrificed the following day. The results demonstrate that delivery of intact, viable mitochondria reduces ischemia-reperfusion injury in the left lung (Figures 31A-31B).
[0265] These results demonstrate that mitochondria can be used to help rescue lungs damaged by ischemia, reperfusion, smoking, or toxins, and can be used to preserve lungs for use in lung transplantation.
[0266] Example 14: Mitochondrial myopathy An experiment was conducted to demonstrate that mitochondria can be delivered to the optic nerve by injecting them into the common carotid artery in mice. PET scan images show that the injected mitochondria are located in the optic nerve (Figure 32).
[0267] These results demonstrate that mitochondrial infusion can be used to treat Leber's hereditary optic neuropathy (LHON) and other mitochondrial myopathies.
[0268] Example 15: Autogenous mitochondrial transplantation for dysfunction after ischemia-reperfusion injury Current treatments for pediatric patients suffering from myocardial ischemia-reperfusion injury include inotropy and mechanical circulatory support. Recovery of myocardial function after extracorporeal membrane oxygenation (ECMO) support is inconsistent, as reflected by a 40% failure to wean from ECMO. Mitochondrial damage and dysfunction contribute significantly to myocardial dysfunction in such patients with ischemia-reperfusion injury. A novel strategy to repair and complement damaged mitochondria, termed "mitochondrial autotransplantation," has been developed in which healthy autogenous mitochondria harvested from non-ischemic skeletal muscle are transplanted into injured myocardium. Examples in this disclosure demonstrate that transplanted mitochondria restore mitochondrial function and viability and improve postischemic myocardial function through internal and external mechanisms, including high-energy synthesis, transcriptome and proteome changes, and DNA repair.
[0269] Patients and methods Pediatric patients who required open-chest ECMO (central ECMO) support due to ischemia-reperfusion-related myocardial dysfunction after cardiac surgery were eligible for mitochondrial autotransplantation. Patients were included if they experienced a postcardiac surgery myocardial ischemic event that did not improve with surgical intervention and ECMO support. Patients were excluded if they underwent ECMO cannulation through a peripheral vascular route (cervical or femoral) (because their access to myocardial injection made them ineligible for this approach).
[0270] Mitochondrial harvesting and isolation can be performed within 20–30 minutes in the same procedure, with minimal manipulation of muscle tissue. The proposed treatment was outlined by two independent physicians not involved in the patient's care, and the family was fully counseled regarding the potential risks of the procedure. The treatment was provided under an Innovative Therapies protocol developed by the Boston Children's Hospital Institutional Review Board.
[0271] In all patients, the mediastinum was accessed and epicardial echocardiography was performed to identify areas of myocardial akinesis or hypokinesis. A 6 mm × 6 mm strip of healthy rectus abdominis muscle was harvested from the inferior aspect of the area using sharp dissection. Autogenous mitochondria (1 × 10 8 ±1×10 5 ) were isolated under sterile conditions and suspended in 1 mL of respiration buffer. 7 ±1×10 4 Ten 100 μL injections containing mitochondria were delivered by direct injection with a 1 mL tuberculin syringe (28-gauge needle) into the ischemia-reperfusion-affected myocardium (as identified by epicardial echocardiography). At the end of the procedure, an epicardial echocardiogram was performed to assess the presence of injection-related myocardial hematoma.
[0272] Echograms were read by a blinded examiner for both global and localized dysfunction segments over the reported time periods.
[0273] result The characteristics and outcomes (mortality and global cardiac function and regional hyposystolic segmentation) of patients who underwent mitochondrial autotransplantation are listed in Table 1. A cardiac segmentation scheme for Table 1 is shown in Figure 33. None of the patients experienced arrhythmias or bleeding related to the epicardial injection. Four of the five subjects demonstrated improvement in ventricular function and were successfully weaned from ECMO support.
[0274] This example describes the use of mitochondrial autotransplantation for myocardial recovery in pediatric patients requiring ECMO support for ischemia-reperfusion injury. None of the patients experienced adverse short-term complications associated with mitochondrial injection (arrhythmias, intramyocardial hematoma, or scarring), and all demonstrated improved ventricular function within a few days of the procedure. Mitochondrial therapy is most advantageous when delivered as early as possible after ischemic injury, as evidenced by studies in animal models. The patients in this series were selected because they showed no recovery of myocardial function despite 1–2 days of ECMO support and showed little spontaneous recovery of ventricular function.
[0275] The mitochondrial dose and delivery method were based on animal studies and extrapolated to cardiac mass in human patients. While epicardial injection was utilized for this study, alternative delivery methods, including transcoronary delivery, are possible.
[0276] Furthermore, there were no detectable differences in pre- and post-injection markers of the systemic inflammatory response syndrome (as evidenced by stable respiratory and renal status), consistent with data from animal studies. Necropsy on patient 1 revealed no signs of inflammation or rejection at the injection site, and there were no clinically relevant changes in white blood cell counts.
[0277] This example demonstrates the first clinical application of a novel technique of mitochondrial autotransplantation, which may be useful for patients with ischemia-reperfusion injury.
[0278] Other Aspects While the present invention has been described in conjunction with the detailed description thereof, it should be understood that the foregoing description is intended to be illustrative and not limiting of the scope of the invention, which is defined by the appended claims. Other aspects, advantages, and improvements are within the scope of the following claims.
[0279] [Table 1] TIFF2024161552000003.tif199152TIFF2024161552000004.tif58148Abbreviation: D-TGA: dextrorotatory great artery transposition HLHS: Hypoplastic left heart syndrome LVOTO: Left ventricular outflow tract obstruction ASO: Aortic switch surgery RmBTS: Right Modified Blalock-Taussick Shunt LCA: left coronary artery POD: Postoperative days DKS: Damus-Kaye-Stansel procedure ECMO: extracorporeal membrane oxygenation LV: left ventricle RV: right ventricle BDG: Bidirectional Glenn procedure
Claims
1. 1. A method of treating a subject having an ischemia-related disease, comprising administering to the subject having an ischemia-related disease a therapeutically effective amount of a composition comprising isolated mitochondria or a combined mitochondrial agent.
2. The method of claim 1 , wherein the composition is administered to the subject by injecting the composition into a blood vessel of the subject.
3. 3. The method of claim 1 or 2, wherein the combined mitochondrial agent comprises a therapeutic agent.
4. 3. The method of claim 1 or 2, wherein the combined mitochondrial agent comprises an imaging agent.
5. 5. The method of claim 4, wherein the imaging agent is radioactive.
6. Imaging material 18 6. The method of claim 5, wherein the compound is F-rhodamine 6G.
7. 5. The method of claim 4, wherein the imaging agent is an iron oxide nanoparticle.
8. 3. The method of claim 1 or 2, wherein the ischemia-related disease is an acute coronary syndrome.
9. 3. The method of claim 1 or 2, wherein the ischemia-related disease is myocardial infarction.
10. 10. The method of claim 9, wherein the blood vessel is a coronary artery of the subject.
11. 3. The method of claim 1 or 2, wherein the ischemia-related disease is hepatic ischemia-reperfusion injury.
12. 12. The method of claim 11, wherein the blood vessel is the hepatic portal vein of the subject.
13. 3. The method of claim 1 or 2, wherein the ischemia-related disease is ischemic injury-compartment syndrome.
14. 3. The method of claim 1 or 2, wherein the mitochondria are autogeneic.
15. 3. The method of claim 1 or 2, wherein the mitochondria are allogeneic.
16. 3. The method of claim 1 or 2, wherein the mitochondria are xenogeneic.
17. 3. The method of claim 1 or 2, further comprising a step of collecting the isolated mitochondria from the cells prior to the administering step, wherein the administering step comprises administering the isolated mitochondria to the subject immediately after the isolated mitochondria are collected from the cells.
18. 1. A method for minimizing cardiac toxicity from chemotherapy in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising isolated mitochondria or a combined mitochondrial agent before, during, or after treatment of the subject with chemotherapy.
19. 20. The method of claim 18, wherein the composition is administered to the subject by injecting the composition into a blood vessel of the subject.
20. 20. The method of claim 18, wherein the combined mitochondrial agent comprises a pharmaceutical agent.
21. 20. The method of claim 19, wherein the blood vessel is a coronary artery of the subject.
22. 1. A method of delivering an active agent to a target site in a subject, comprising administering a therapeutically effective amount of a combined mitochondrial agent to a blood vessel of the subject.
23. 23. The method of claim 22, wherein the target site is the subject's heart, kidney, pancreas, lung, optic nerve, brain, or skeletal muscle.
24. 23. The method of claim 22, wherein the blood vessel is part of a subject's vascular system that carries blood to a target site.
25. 23. The method of claim 22, wherein the combined mitochondrial agent comprises a pharmaceutical agent covalently linked to the mitochondria.
26. 23. The method of claim 22, wherein the combined mitochondrial agent comprises a pharmaceutical agent embedded in the mitochondria.
27. 23. The method of claim 22, wherein the combined mitochondrial agent comprises a therapeutic agent.
28. 23. The method of claim 22, wherein the combined mitochondrial agent comprises a diagnostic agent.
29. 23. The method of claim 22, wherein the combined mitochondrial agent comprises an antibody or antigen-binding fragment.
30. 1. A method of imaging tissue of a subject, comprising: a) administering to the subject an effective amount of a combined mitochondrial agent that includes an imaging agent; and b) imaging said tissue of said subject with an imaging technique.
31. Imaging material 18 31. The method of claim 30, wherein the F-labeled rhodamine 6G is F-labeled rhodamine 6G.
32. 31. The method of claim 30, wherein the imaging agent is an iron oxide magnetic nanoparticle.
33. 1. A method of making a combined mitochondrial agent, comprising: 1) isolating mitochondria from cells; 2) mixing the mitochondria with an effective amount of a therapeutic, diagnostic, or imaging agent under conditions sufficient to allow for attachment of the therapeutic, diagnostic, or imaging agent to the mitochondria.
34. The mitochondria are mixed with an imaging agent, and the imaging agent is 18 34. The method of claim 33, wherein the compound is F-rhodamine 6G.
35. 34. The method of claim 33, wherein the mitochondria are mixed with an imaging agent, and the imaging agent is an iron oxide nanoparticle.
36. 1. A method of making a pharmaceutical substance comprising a combined mitochondrial agent, the method comprising: Providing a combined mitochondrial agent; and mixing the combined mitochondrial agent with a pharma- ceutically acceptable carrier.
37. 37. The method of claim 36, wherein the pharma- ceutically acceptable carrier is a respiration buffer.
38. 1. A method for treating a mitochondrial dysfunction disorder in a subject, comprising administering to a subject having a mitochondrial dysfunction disorder a therapeutically effective amount of a pharmaceutical composition comprising isolated mitochondria or a combined mitochondrial agent.
39. 40. The method of claim 38, wherein the composition is administered to the subject by injecting the composition into a blood vessel of the subject.
40. 40. The method of claim 38 or 39, wherein the mitochondrial dysfunction disorder is Kearns-Sayre syndrome, MERRF syndrome, MELAS syndrome or Leber's disease.
41. 40. The method of claim 38 or 39, wherein the mitochondrial dysfunction disorder is Barth Syndrome.
42. 40. The method of claim 38 or 39, wherein the mitochondrial dysfunction disorder is diabetes.
43. 43. The method of claim 42, wherein the blood vessel is the great pancreatic artery of the subject.
44. 40. The method of claim 38 or 39, wherein the mitochondrial dysfunction disorder is Parkinson's disease.
45. 40. The method of claim 38 or 39, wherein the pharmaceutical composition comprises a combined mitochondrial agent that comprises a pharmaceutical agent.
46. 40. The method of claim 38 or 39, wherein the mitochondria are autologous.
47. The method of claim 46, wherein the autologous mitochondria have exogenous mtDNA.
48. 40. The method of claim 38 or 39, wherein the mitochondria are from the same species.
49. 40. The method of claim 38 or 39, wherein the mitochondria are from a first-degree relative of the subject.
50. 40. The method of claim 38 or 39, wherein the mitochondria are of heterologous origin.
51. 1. A method for minimizing reperfusion injury in an organ, comprising injecting an effective amount of isolated mitochondria or a combined mitochondrial agent into the blood vessels of the organ before, during, or after reperfusion injury occurs in the organ.
52. 52. The method of claim 51, wherein the organ is treated in situ or ex vivo.
53. 52. The method of claim 51, wherein the organ is a transplant organ.
54. 52. The method of claim 51, wherein the organ is the brain.
55. 52. The method of claim 51, wherein the organ is the heart.
56. 52. The method of claim 51, wherein the organ is a kidney.
57. 1. A method of treating cancer in a subject comprising administering a therapeutically effective amount of a combined mitochondrial agent to a blood vessel of a subject having cancer, wherein the combined mitochondrial agent comprises a cytotoxic agent.
58. 58. The method of claim 57, wherein the cancer is prostate cancer, ovarian cancer, or neuroblastoma.
59. 58. The method of claim 57, wherein the blood vessel is a prostatic artery of the subject.
60. 1. A method of treating a mitochondrial defect in an egg or embryo cell, comprising: 1) obtaining an effective number of mitochondria from a subject; and 2) contacting said cells with said effective number of mitochondria.
61. 61. The method of claim 60, wherein the egg cells are prepared for in vitro fertilization.
62. 61. The method of claim 60, wherein the embryonic cells are prepared during in vitro fertilization.
63. 61. The method of claim 60, wherein the subject is a male who will provide sperm for in vitro fertilization.
64. 1. A method for improving mitochondrial function in a cell, comprising the step of contacting the cell with isolated mitochondria or a combined mitochondrial agent in an amount sufficient to improve mitochondrial function in the cell.
65. 65. The method of claim 64, wherein the cell is a stem cell.
66. 1. A method for improving mitochondrial function in a tissue of a subject, comprising administering to the tissue a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to improve mitochondrial function in the tissue.
67. 67. The method of claim 66, wherein the tissue is skin tissue, facial muscle, bone marrow tissue, or white adipose tissue.
68. 67. The method of claim 66, wherein the composition is administered to the tissue by injecting the composition into the tissue.
69. 1. A method of increasing blood flow or decreasing vascular resistance in an organ of a subject, the method comprising: Administering a composition comprising isolated mitochondria or combined mitochondrial agents to the subject in an amount sufficient to increase blood flow or decrease vascular resistance.
70. 70. The method of claim 69, wherein the organ is the heart, lung, kidney, brain, or skeletal muscle.
71. 70. The method of claim 69, wherein the isolated mitochondria or the combined mitochondrial agents are administered to the subject within 30 minutes, 40 minutes, 50 minutes, or 60 minutes from the time the mitochondrial isolation process begins.
72. 70. The method of claim 69, wherein the composition is injected into a coronary artery before, during, or after cardiac surgery.
73. 70. The method of claim 69, wherein the composition is administered to the subject by injecting the composition into a blood vessel that carries blood to the organ.
74. 1. A method for removing a blockage in a blood vessel in a subject, comprising the step of injecting into said blood vessel a composition comprising isolated mitochondria or a combined mitochondrial agent.
75. 75. The method of claim 74, wherein the subject has peripheral vascular disease.
76. 75. The method of claim 74, wherein the composition is injected into a blood vessel within about 30 minutes, 40 minutes, 50 minutes, or 60 minutes from the time the mitochondrial isolation process begins.
77. 1. A method of transplanting cells or tissue into a subject, the method comprising: contacting the cell or tissue with an effective amount of a composition comprising isolated mitochondria or an isolated mitochondrial agent; and Transplanting said cells or said tissue into said subject.
78. 78. The method of claim 77, wherein the cell is a stem cell.
79. 78. The method of claim 77, wherein the tissue is bone marrow.
80. 1. A method for improving mitochondrial function in a cell or tissue, comprising the step of contacting the cell or tissue with an effective amount of a composition comprising isolated mitochondria or a combined mitochondrial agent, thereby improving mitochondrial function in the cell or tissue.
81. The method of claim 80, wherein the cell is a transplant cell.
82. 81. The method of claim 80, wherein the cell is a stem cell.
83. 81. The method of claim 80, wherein the tissue is a transplant tissue.
84. 81. The method of claim 80, wherein the tissue is bone marrow tissue.
85. 1. A method of treating a wound in a subject, comprising administering to a wound area of the subject a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to treat the wound.
86. 86. The method of claim 85, wherein the wound is an open wound or a burn wound.
87. 86. The method of claim 85, wherein the composition is administered by injecting the composition into the wound tissue.
88. 1. A method of treating a subject having a metabolic disorder, comprising administering to white adipose tissue of the subject a composition comprising isolated mitochondria or combined mitochondrial agents in an amount sufficient to treat the metabolic disorder.
89. 89. The method of claim 88, wherein the metabolic disorder is obesity or type II diabetes.
90. 89. The method of claim 88, wherein the composition is administered by injecting the composition into white adipose tissue.
91. A method for increasing mitochondrial function in white adipose tissue of a subject, comprising the step of administering to the white adipose tissue a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to increase mitochondrial function.
92. 92. The method of claim 91, wherein the composition is administered by injecting the composition into white adipose tissue.
93. 1. A method for reducing fat deposits in a subject, comprising administering to the fat deposits a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to reduce fat deposits in the subject.
94. 94. The method of claim 93, wherein the adipose tissue is white adipose tissue.
95. 94. The method of claim 93, wherein the fat problem is located under the chin or in the abdomen of the subject.
96. 1. A method for treating skin wrinkles or scarring in a subject, comprising administering to an area of skin wrinkles or scarring a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to treat the skin wrinkles or scarring.
97. 97. The method of claim 96, wherein the composition is administered by a 28, 29, 30, 31, 32, 33, or 34 gauge hypodermic needle.
98. 1. A method for improving mitochondrial function in the skin of a subject, comprising administering to the subject a composition comprising isolated mitochondria or a combined mitochondrial agent in an amount sufficient to improve mitochondrial function in the skin of the subject.
99. 99. The method of claim 98, wherein the composition is administered by injecting the composition into skin tissue.
100. 99. The method of claim 98, wherein the composition is administered by a 28, 29, 30, 31, 32, 33, or 34 gauge hypodermic needle.
101. Isolated mitochondria or combined mitochondrial agents; and Carrier A composition comprising:
102. 102. The composition of claim 101, which is a pharmaceutical composition.
103. The composition of claim 101 or 102, wherein the combined mitochondrial agent comprises a therapeutic agent.
104. The composition of claim 101 or 102, wherein the combined mitochondrial agent comprises an imaging agent.
105. 105. The composition of claim 104, wherein the imaging agent is radioactive.
106. The imaging material is 18 105. The composition of claim 104, which is F-rhodamine 6G, or iron oxide nanoparticles.
107. The composition of claim 101 or 102, wherein the combined mitochondrial agent comprises a diagnostic agent.
108. The composition of claim 101 or 102, wherein the combined mitochondrial agent comprises a pharmaceutical agent covalently linked to the mitochondria.
109. The composition of claim 101 or 102, wherein the combined mitochondrial agent comprises a pharmaceutical agent embedded in the mitochondria.
110. The composition of claim 101 or 102, wherein the combined mitochondrial agent comprises an antibody or antigen-binding fragment.
111. The composition of claim 101 or 102, wherein the mitochondria are autologous, allogeneic, or xenogeneic.
112. The composition of claim 101 or 102, wherein the mitochondria carry exogenous DNA.
113. 103. The composition of claim 101 or 102, wherein the carrier is a respiratory buffer or a mitochondrial buffer.
114. 103. The composition of claim 101 or 102, wherein the carrier is University of Wisconsin (UW) fluid.
115. 103. The composition of claim 101 or 102, wherein the carrier is blood or serum.
116. 103. The composition of claim 101 or 102, wherein the carrier is an imaging agent.
Citation Information
Patent Citations
Methods and compositions for mitochondrial replacement therapy
US20110008310A1
Mitochondrial enhancement of cells
US20120107285A1
Method and applications of peptide-mediated mitochondrial delivery system
US20140178993A1
Compositions Of Functional Mitochondria And Uses Thereof
US20140193511A1
Products and methods to isolate mitochondria
WO2015192020A1
